 	Population	Intervention	Assessment tool(s)a	Analysis

Papers	Randomization	Justification of sample size	Control group	Allocation concealment	Underlying theory	Validity	Reliability	Intention-to-treat	Attrition rate

Alonso, Fernandez, Mataix et al. (1999)	No	Not mentioned	No	N/A	None	N/A	N/A	N/A	N/A

Beasley, Capossela, Brigham, Gunderson and Gortmaker (1997)	No	No	No	N/A	None	N/A	N/A	N/A	N/A

Bleakley (2010)	No	No	No	N/A	None	N/A	N/A	N/A	N/A

Dettle, Sagel and Chrysler (1994)	No	No	Yes (but no statistical comparison between groups)	Not mentioned	None	Not mentioned	Not mentioned	no	40% attrition;

No analysis of dropouts

Kittur, McMenamin and Knott (1990)	No	No	Yes	Not randomly assigned	None	N/A	N/A	N/A	N/A

Light (1987)	No	No	Yes (but no statistical comparison between groups)	Not randomly assigned	None	N/A	N/A	N/A	N/A

Milanés, Gonzalez, Hernandez, Arminio, Clesca and Rivas-Vetencourt (2003)	No	No	No	N/A	None	N/A	N/A	N/A	N/A

Nelson, Marymont, Durand, Reyes and Davis (1992)	Random cluster probability method	No	Yes	Not randomly assigned	None	Field testing of the questionnaire (but validity/reliability assessment not detailed)	N/A	N/A

Niday, Painter, Peak et al. (2007)	No	No	No	N/A	None	N/A	N/A	N/A	N/A

Riker and White (1995)	No	No	Yes	Not randomly assigned	None	N/A	N/A	N/A	N/A

Shafer, Durand, Hueneke, et al. (1998)	No	No	No	N/A	None	N/A	N/A	N/A	N/A

Stark, Wikoren and Martone (1994)	No	No	No	N/A	None	N/A	N/A	N/A	N/A

Taylor, Young and Kneteman (1997)	No	No	No	N/A	‘Change theory’ (not referenced)	N/A	N/A	N/A	N/A

Van Gelder, Van Hees, de Roey, Monbaliu, Aerts, Coosemans et al. (2006)	No	No	No	N/A	None	N/A	N/A	N/A	N/A

Wight, Cohen, Roels and Miranda (2000)	No	No	No	N/A	None	N/A	N/A	N/A	N/A


Disease	Regimen	No. pts.	PFS	Efficacy	Ref.

Metastatic head and neck cancer	Vorinostat: 400 mg orally daily	13		SD 2 pts. OR 0%	[51]

Metastatic breast cancer	Vorinostat: 400 mg orally daily	14		SD 4 pts	[52]

Relapsed NSCLC	Vorinostat: 400 mg or 300 mg once daily on days 1–14 of the 21 day cycle	16	Median: 2.3 m. 	SD 57%	[53]

Metastatic prostate cancer	Vorinostat: 400 mg orally daily	27	Median: 2.8 m. 	SD 2 pts.	[54]

Ovarian or primary peritoneal carcinoma	Vorinostat: 400 mg orally daily	27		PR 1 pt.	[55]

Recurrent GBM 	Vorinostat: 200 mg p.o.twice a day for 14 days, followed by a 7-day rest period	66	6-m.-PFS: 9 of the first 52 patients	OR 2 pts.	[56]

Metastatic colorectal cancer	Vorinostat: 800 or 1,400 mg/day once a day × 3 days, every 2 weeks +5-FU: preceded by leucovorin, at 400 mg/m2 followed by a 46 h infusion at 2.400 mg/m2 on days 2–3 	58	PFS rate did not reach the threshold of 27 out of 43 patients	PR 1 pt.	[57]

Untreated stage IIIB or IV NSCLC	Vorinostat: 400 mg or Placebo on days 1 through 14 of each 3-week cycle +Carboplatin: AUC 6 +Paclitaxel: 200 mg/m2, both on day 3 of each 21-day cycle	94	Median: Vorinostat: 6.0 m. Placebo: 4.1 m. P = ns	RR Vorinostat: 34% Placebo: 12.5% P = 02	[58]

Advanced thyroid cancer	Vorinostat: 400 mg orally daily	19		SD 56% OR 0	[59]

Recurrent GBM	Vorinostat: 400 mg daily for 14 days of a 21-day cycle + Bortezomib: 1.3 mg/m2 intravenously on days 1,4, 8, and 11 of a 21-day cycle	37	Median: 1.5 m. 	PR 1 pt.	[60]


Bacteria, plasmid, or gene	Relevant features or sequence (5′–3′)	References or sources

Bacteria

 E. coli DH5α	endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR F- Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK- mK +), λ–	Invitrogen

 L. lactis NZ9000	MG1363 nisRK ΔpepN	NIZO [35, 36]

 Lb. plantarum ATCC 8014	Wild type	ATCC

Plasmid

 pNZ8148	pSH71 derivative, PnisA, CmR, nisin-controlled expression	NIZO [35, 36]

 pNZRK	pNZ8148 containing nisR and nisK genes	This work

 pNZ-IRFP713	pNZ8148 containing irfp713 gene	This work

 pNZ-IRFP682	pNZ8148 containing irfp682 gene	This work

 pNZRK-IRFP713	pNZ8148 containing irfp713, nisR and nisK genes	This work

 pMA-T-IRFP713	pMA-T containing irfp713 gene	This work

 pMSP3545	Emr, PnisA, nisRK, NcoI for translational fusion, ColE1 and pAMβ1 replicons	[37]

 pMSP3545-IRFP713	pMSP3545 containing irfp713 gene	This work

 pGEM::CP25-IRFP	pGEM-T Easy containing irfp713 gene under the control of CP25 promoter	[27]

Gene

 irfp713	<underline>CCATGG</underline>CTGAGGGATCTGTAGCTCGTCAACCTGATTTACTTACTTGTGACGATGAACCTATTCATATTCCAGGTGCTATTCAACCACACGGACTTTTATTAGCTCTTGCCGCTGACATGACTATCGTCGCTGGATCAGATAATTTACCTGAATTGACTGGTTTAGCAATTGGAGCCCTTATTGGACGATCAGCAGCAGATGTTTTTGATTCAGAAACTCATAATCGTCTTACTATTGCATTGGCAGAACCTGGTGCTGCAGTAGGTGCTCCTATTACAGTAGGTTTCACTATGCGTAAGGATGCTGGTTTTATTGGTTCTTGGCATCGTCATGATCAACTTATTTTTTTAGAGTTGGAACCACCACAAAGAGACGTTGCAGAGCCTCAAGCTTTTTTTCGTCGTACTAATTCAGCAATTCGTAGACTTCAAGCTGCTGAAACTCTTGAATCTGCATGTGCAGCAGCAGCACAAGAGGTACGAAAAATTACAGGTTTTGATAGAGTTATGATTTACAGATTTGCCTCAGACTTTTCTGGTGAAGTAATCGCAGAGGATAGATGTGCCGAGGTTGAAAGTAAATTGGGATTGCATTATCCTGCCAGTACTGTTCCAGCCCAAGCACGTCGTCTTTATACTATTAATCCTGTTAGAATTATCCCAGATATTAATTATCGACCAGTTCCAGTTACTCCTGACTTAAATCCTGTAACTGGTAGACCTATTGACTTGTCATTTGCCATCTTACGATCTGTTTCACCTGTTCATTTAGAGTTTATGCGTAATATTGGTATGCATGGTACTATGTCTATCTCAATCCTTCGAGGAGAACGTTTATGGGGACTTATTGTTTGTCATCATAGAACACCTTATTATGTCGATTTAGATGGACGTCAAGCTTGTGAATTAGTTGCTCAAGTCTTGGCTTGGCAAATTGGTGTAATGGAAGAATAA<underline>TCTAGA</underline>	This work

Primers

 nisR-F	GATGATAAGCTGTCCAAAC	This work

 nisK-R	TTTAGGATAACTTCTGCCC	This work

 682-1F	CTCAGACTTTTCTGGTGTAGTAATCGCAGAGGATAG	This work

 682-2F	GCATTATCCTGCCAGTGCTGTTCCAGCCCAAGC	This work

 682-3F	CCATCTTACGATCTGTTTCACCTTGTCATTTAGAGTTTATGCG	This work

 682-1R	CTATCCTCTGCGATTACTACACCAGAAAAGTCTGAG	This work

 682-2R	GCTTGGGCTGGAACAGCACTGGCAGGATAATGC	This work

 682-3R	CGCATAAACTCTAAATGACAAGGTGAAACAGATCGTAAGATGG	This work


Predictors	Model 8	95% CI

Fixed effects

 Intercept	−0.81 *	(0.35)	−1.55	−0.09

 Ego gender	0.25	(0.51)	−0.80	1.30

 Change in activity scorea	0.38 **	(0.11)	0.16	0.59

 Change in contact frequencya	−0.71 ***	(0.17)	−1.03	−0.38

 Participant mean change in activity score	0.18	(0.24)	−0.31	0.68

 Participant mean change in contact frequency	−0.20	(0.27)	−0.76	0.35

 Gender × change in activity score	0.35 *	(0.15)	0.06	0.64

 Gender × change in contact frequency	0.51 *	(0.25)	0.03	1.00

Covariance parameters

 Random intercept (participants)	1.12 **	(0.38)	0.58	2.20


miRNA	RT (Primer)	PCR (Forward primer)	PCR (Reverse primer)

mir-144	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAGTACA	CGGCCGGTACAGTATAGATGA	GTGCAGGGTCCGAGGT

mir-106b*	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGCAGCA	AATGCCGCACTGTGGGTACT	GTGCAGGGTCCGAGGT

mir-669k*	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGCACAC	GCCCGGTGTGCATGTGTGTATAGTT	GTGCAGGGTCCGAGGT

mir-142-3p	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTCCATA	GCGCTGTAGTGTTTCCTACTT	GTGCAGGGTCCGAGGT

mir-223	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTGGGGT	CCGCCCGTGTCAGTTTGTCAAAT	GTGCAGGGTCCGAGGT

mir-210	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTCAGCC	AATCCTGTGCGTGTGACAGC	GTGCAGGGTCCGAGGT

mir-32*	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAATATC	CGCGCGGCCAATTTAGTGTGTGT	GTGCAGGGTCCGAGGT

mir-669C	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCACACAC	CGCGCCATAGTTGTGTGTGGAT	GTGCAGGGTCCGAGGT

mir-466i-5p	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCACACA	CGCCCTGTGTGTGTGTGTG	GTGCAGGGTCCGAGGT

mir-122*	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTTAGTG	CGCCCAAACGCCATTATCA	GTGCAGGGTCCGAGGT

mir-34C*	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCCTGGC	GCCCAATCACTAACCACACA	GTGCAGGGTCCGAGGT

mir-541*	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAGTATG	ACACCCTGGCGAACACAGAATC	GTGCAGGGTCCGAGGT

U6		CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT


Quality Index items	Imamura et al. (1998)	Tillu and Gupta (1998)	Perez Millan and Foster (2001)

Reporting

1. Study hypothesis/aim/objective	1	1	1

2. Main outcomes	1	1	1

3. Characteristics of the participants	0	0	0

4. Interventions of interest	0	1	0

5. Distributions of principal confounders in each group	0	0	0

6. Main findings	0	1	1

7. Estimates of random variability for main outcomes	1	0	1

8. All the important adverse events that may be a consequence of intervention	0	0	0

9. Characteristics of patients lost to follow-up	0	1	1

10. Actual probability values for main outcomes	0	1	0

External validity

11. Were subjects who were asked to participate representative of the entire population from which they were recruited?	1	1	0

12. Were subjects who were prepared to participate representative of the entire population from which they were recruited?	0	0	0

13. Were the staff, places, and facilities representative of the treatment the majority of subjects received?	1	0	1

Internal validity (bias)

14. Was an attempt made to blind subjects to the intervention they received?	0	0	0

15. Was an attempt made to blind those measuring main outcomes of the intervention?	0	0	0

16. If any of the results of the study were based on"data dredging", was this made clear?	0	1	1

17. Do analyses adjust for different lengths of follow-up?	0	1	1

18. Were appropriate statistical tests used to assess the main outcomes?	1	1	1

19. Was compliance with the intervention reliable?	1	1	1

20. Were main outcome measures reliable and valid?	0	0	0

Internal validity (selection bias)

21. Were patients in different intervention groups recruited from the same population?	0	0	0

22. Were subjects in different intervention groups recruited over the same period of time?	0	0	0

23. Were subjects randomized to intervention groups?	0	0	0

24. Was the randomized intervention assignment concealed from both patients and staff until recruitment was complete and irrevocable?	0	0	0

* 25. Was there adequate adjustment for confounding in the analyses from which main findings were drawn?	x	x	x

26. Were losses of subjects to follow-up taken into account?	0	1	1

Power

* 27. Did the study have sufficient power to detect a clinically important effect where the probability for a difference due to chance was less than 5%?	x	x	x

Total score (/27)	7	12	11


Paraclinical findings	Number a(%)	Number b (%)

Chest X ray

Normal	98 (94,2)	57 (96,6)

Abnormal	6 (5,8)	3 (5,1)

Cardiomegaly	2 (1,9)	1 (1,7)

Enlargement of the superior mediastinum	3 (2,9)	1 (1,7)

Interstitial Syndrome	1 (1)	0

Spirometry

Normal	94 (90,4)	56

Restrictive profile	7 (6,7)	1 (1,7)

Obstructive ventilatory defect	3 (2,9)	2 (3,4)

Electrocardiogram

Normal	92 (88,5)	54

Abnormal	12 (11,5)	5 (8,5)

Right atrial hypertrophy	10 (9,6)	4 (6,8)

Arrhythmia	2 (1,9)	1 (1,7)


PANTHER Pathways	Annotated	Dapulian (DT_DC)	Landrace (LT_LC)

Significant	Expected	Fold Enrichment	p-Value	Significant	Expected	Fold Enrichment	p-Value

Angiogenesis (P00005)	147	27	13.37	2.02	6.50 × 10−4	27	14.56	1.85	2.16 × 10−3

Cholecystokinin receptor(CCKR) signaling map (P06959)	155	30	14.1	2.13	1.43 × 10−4	23	15.35	1.5	4.00 × 10−2

Epidermal growth factor (EGF) receptor signaling pathway (P00018)	134	24	12.19	1.97	1.73 × 10−3	23	13.27	1.73	9.35 × 10−3

Fibroblast growth factor (FGF) signaling pathway (P00021)	124	21	11.28	1.86	5.97 × 10−3	19	12.28	1.55	4.47 × 10−2

Parkinson disease (P00049)	104	20	9.46	2.11	1.82 × 10−3	23	10.3	2.23	4.26 × 10−4

PI3 kinase pathway (P00048)	45	10	4.09	2.44	9.36 × 10−3	11	4.46	2.47	6.18 × 10−3

Ras Pathway (P04393)	80	22	7.28	3.02	7.76 × 10−6	14	7.92	1.77	3.17 × 10−2

T cell activation (P00053)	83	16	7.55	2.12	4.81 × 10−3	15	8.22	1.82	2.11 × 10−2

Toll receptor signaling pathway (P00054)	59	10	5.37	1.86	4.69 × 10−2	11	5.84	1.88	3.63 × 10−2

Ubiquitin proteasome pathway (P00060)	65	11	5.91	1.86	3.89 × 10−2	13	6.44	2.02	1.48 × 10−2

Gonadotropin releasing hormone receptor pathway (P06664)	223	41	20.28	2.02	3.09 × 10−5	–	–	–	–

Apoptosis signaling pathway (P00006)	129	24	11.73	2.05	1.06 × 10−3	–	–	–	–

Fas signaling pathway (P00020)	41	11	3.73	2.95	1.65 × 10−3	–	–	–	–

Vascaular endothelial growth factor (VEGF) signaling pathway (P00056)	61	13	5.55	2.34	4.71 × 10−3	–	–	–	–

Integrin signaling pathway (P00034)	153	24	13.92	1.72	8.50 × 10−3	–	–	–	–

p53 pathway feedback loops 2 (P04398)	53	11	4.82	2.28	1.06 × 10−2	–	–	–	–

De novo purine biosynthesis (P02738)	46	10	4.18	2.39	1.08 × 10−2	–	–	–	–

Oxidative stress response (P00046)	29	7	2.64	2.65	1.83 × 10−2	–	–	–	–

Transforming growth factor beta(TGF-β) signaling pathway (P00052)	90	15	8.19	1.83	2.04 × 10−2	–	–	–	–

Hypoxia response via HIF activation (P00030)	30	7	2.73	2.57	2.15 × 10−2	–	–	–	–

Platelet derived growth factor (PDGF) signaling pathway (P00047)	141	21	12.82	1.64	2.17 × 10−2	–	–	–	–

Interleukin signaling pathway (P00036)	101	16	9.19	1.74	2.56 × 10−2	–	–	–	–

Inflammation mediated by chemokine and cytokine signaling pathway (P00031)	228	30	20.74	1.45	3.19 × 10−2	–	–	–	–

Heme biosynthesis (P02746)	14	4	1.27	3.14	4.04 × 10−2	–	–	–	–

Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade (P00032)	35	7	3.18	2.2	4.35 × 10−2	–	–	–	–

p53 pathway (P00059)	92	14	8.37	1.67	4.60 × 10−2	–	–	–	–

Coenzyme A biosynthesis (P02736)	11	–	–	–	–	5	1.09	4.59	5.21 × 10−3

Salvage pyrimidine ribonucleotides (P02775)	13	–	–	–	–	5	1.29	3.88	1.02 × 10−2

B cell activation (P00010)	68	–	–	–	–	13	6.74	1.93	2.05 × 10−2

General transcription regulation (P00023)	34	–	–	–	–	8	3.37	2.38	2.19 × 10−2

Lysine biosynthesis (P02751)	6	–	–	–	–	3	0.59	>5	2.25 × 10−2

Insulin/insulin-like growth factor (IGF) pathway-protein kinase B signaling cascade (P00033)	49	–	–	–	–	10	4.85	2.06	2.67 × 10−2

Angiotensin II-stimulated signaling through G proteins and β-arrestin (P05911)	30	–	–	–	–	7	2.97	2.36	3.20 × 10−2

Notch signaling pathway (P00045)	40	–	–	–	–	8	3.96	2.02	4.88 × 10−2


Diagnosis

Guillain-Barré syndrome, n (%)	26 (63.4)

Autoimmune encephalitis, n (%)	6 (14.6)

Miller-Fisher syndrome, n (%)	2 (4.9)

Chronic relapsing inflammatory optic neuropathy (CRION), n (%)	1 (2.4)

Multiple sclerosis, n (%)	1 (2.4)

Parainfectious myelitis, n (%)	1 (2.4)

Myasthenia gravis, n (%)	1 (2.4)

Anti-Yo-associated paraneoplastic cerebellar degeneration, n (%)	1 (2.4)

Anti-Hu-associated polyneuropathy, n (%)	1 (2.4)

Neuromyelitis optica, n (%)	1 (2.4)


Variables	Algorithm

P(X) = base rate of event for person X	Produce a time series for C and S events:

P(X|Y) = rate of event for X given Y did

P(X|X) = probability of event repetition	Do 1000 timesIf rand < P(C)C outputs event (=1)Else if rand < P(C|C) and C = 1C outputs eventOtherwiseC outputs no event (=0)If rand < P(S|C) and C = 1S outputs event (=1)Else if rand < P(S)S outputs eventElse if rand < P(S|S) and S = 1S outputs eventOtherwiseS outputs no event (=0)


	Disability screening but not in regression model	In regression model	p Value	Number of missing values/4219 (%)

Allocation to intervention in original trial	316/901 (35%)	1786/3318 (54%)	<0.001

Household appliance score: none of assets on list	475/901 (53%)	1754/3318 (53%)	0.801

Household appliance score: most expensive assets	58/901 (6%)	187/3318 (6%)

Positive disability screen	73/901 (8%)	241/3318 (7%)	0.395

Included in initial regression model but dropped from final model

 Four skilled antenatal care visits	87/901 (10%)	296/3315 (9%)	0.501	3 (<1%)

 Possible symptoms of preeclampsia	499/873 (57%)	1697/3210 (53%)	0.024	136 (3%)

 Delivery room heated	681/901 (76%)	2651/3318 (80%)	0.005	0

 Infant had fever in neonatal period	156/901 (17%)	489/3318 (15%)	0.057	0

Retained in final logistic regression model

 Maternal underweight (BMI<18∙5)	89/675 (13%)	382/3318 (12%)	0.220	226 (5%)

 Mother cohabited with husband when <16 years old	178/716 (25%)	812/3318 (24%)	0.827	185 (4%)

 Skilled birth attendant	18/733 (3%)	91/3318 (3%)	0.664	168 (4%)

 Infant size ‘very small’	12/901 (1%)	108/3318 (3%)	0.002	0

 Infant illness: diarrhoea and repeated vomiting	46/901 (5%)	159/3318 (5%)	0.698	0

 Mean weight in grams at 1 month (SD)	4395(963) n=335	4271(898) n=3318	0.017	566 (13%)


Prediction set	Published [14]	BRAKER1/soft-masked

Number of protein coding genes predicted	20,964	15,747

Mean protein length (amino acids)	218.8	344.5

Number of single exon genes	1,728	2,326

Mean number of exons per genea	5.9	7.8

Proportion of noncanonical (GC-AG) introns	8.87%	0.79%

Percentage mapping to publicly available transcriptome reads

Sanger ESTs	80.45%	84.26%

Roche 454 reads	37.18%	58.03%

BUSCO score for proteome

Complete	47.8%	94%

Fragmented	34.7%	4.3%

Number of proteins with no hits in Uniref90	8,962	2,889

Protein singletons in clustering	5,442	1,112

Conserved, single-copy orthologuesb

Total	2,089	2,330

Missing	377	141

Expanded	184	84


Organism	Group	tag	Lanes in Figure 2

Gallus gallus	Animals	CACTCACAAGCTCGACGTACAC	1 and 8

Canis familiaris	Animals	CAGACAGCACTCGTTCGTACAC	2 and 9

Arabidopsis thaliana	Plants	GACTGAACGTGCTCTGCTACTG	3 and 10

Sulfolobus acidocaldarius str. DSM639	Crenarchaeota	CAGTCACAGCACACGAGTACAC	4 and 11

Bartonella henselae str. Houston-1	Alphaproteobacteria	CAGACACGAGCAACGACTACAC	5 and 12

Bartonella henselae str. UGA 8	Alphaproteobacteria	CAGACACGAGCAACGACTACAC	6 and 13

Anabaena PCC7120	Cyanobacteria	CACTCTGTGCTCGTTGCTACAC	(Figure 3)

Synechocystis PCC 6803	Cyanobacteria	CAGACAGCAAGCAGCACTACAC	(Figure 3)


Breast Clinicopathological details	Cancer	Fibroadenoma	Normal

Number of patients	103	35	30

Median Patient Age yrs	56 (35-90)	44 (17-62)	46.5 (24-58)

Menopausal Status

Post	72

Pre	32

Histological Subtype

Invasive Ductal	78

Invasive Lobular	11

Other	14

Intrinsic Subtype

Luminal A (ER/PR+, HER2/neu-)	42

Luminal B (ER/PR+, HER2/neu+)	18

HER2 Over expressing (ER-, PR-, HER2/neu+)	16

Triple-Negative (ER-, PR-, HER2/neu-)	16

Unknown	11

Tumour Grade

1	5

2	32

3	55

Tumour size

1	19

2	39

3	10

UICC Stage

Stage 1	23

Stage 2	36

Stage 3	21

Stage 4	10


	Participants from wards with high staff moralea (n = 12)	Participants from wards with low staff moralea (n = 9)

Gender	50 % (6/12) male; 50 % (6/12) female	89 % (8/9) male; 11 % (1/9) female

Age	25 % (3/12) 16–17 years	22 % (2/9) 18–25 years

8 % (1/12) 18–25 years	33 % (3/9) 26–35 years

25 % (3/12) 26–35 years	11 % (1/9) 36–45 years

16 % (2/12) 36–45 years	33 % (3/9) 46–55 years

8 % (1/12) 46–55 years

16 % (2/12) 56–65 years

Ethnicity	50 % (6/12) British or White British	33 % (3/9) British or White British

17 % (2/12) White & Black Caribbean	22 % (2/9) Black African

8 % (1/12) Indian	11 % (1/9) Caribbean

8 % (1/12) White other	11 % (1/9) Black other

8 % (1/12) Black other	11 % (1/9) Asian

8 % (1/12) Mixed ethnicity	11 % (1/9) Mixed ethnicity

Ward type	25 % (3/12) Female acute ward	33 % (3/9) Male psychiatric intensive care unit

	25 % (3/12) Mixed gender recovery unit	33 % (3/9) Male acute ward

	25 % (3/12) Mixed gender child and adolescent unit	33 % (3/9) Mixed gender acute ward

	25 % (3/12) Male rehabilitation unit


Parameter		BSP	Control	P

Gender	Male	62	65	>0.05

	Female	38	35

Age	≤40	33	29	>0.05

	>41	67	71

Etiology	Trauma	31	31	>0.05

	Other	69	69


	Group 1 (n = 33) admitted to HSS	Group 2 (n = 27) admitted to RS	P valuea)

Total number	Mean per patient	SD	Total number	Mean per patient	SD

Specialist health care services

In-patient days (total number)	245	7.4	12.1	300	11.1	22.1	0.872

Number in-patient days at HSS	118	3.6	7.0	156	5.8	11.7	0.621

Number in-patient days at RS	117	3.5	6.4	131	4.9	11.4	0.813

Number in-patient days other hospitals	10	0.3	1.0	13	0.5	1.5	0.952

Out-patient/X-ray consult. (total number)	70	2.1	3.0	37	1.4	2.3	0.201

Out-patient/X-ray consultations at HSS	26	0.8	1.4	6	0.2	0.5	0.044*

Out-patient/X-ray consultations at RS	29	0.9	1.3	16	0.6	1.0	0.318

Out-patient/X-ray consult. other hospitals	15	0.5	0.9	15	0.6	1.4	0.752

Municipal health care services

Nursing homes (days)	355	10.8	30.0	524	19.4	50.0	0.078

Home care total (hours)	2415	73.2	136.2	3019	111.8	245.6	0.796

Home nursing (hours)	1983	60.1	117.6	2669	98.9	227.4	0.856

Practical help (hours)	432	13.1	26.4	350	13.0	24.0	0.970

GP office consultations (number)	470	14.2	11.8	352	13.0	13.3	0.562

GP consultations (number)	263	8.0	7.2	193	7.2	7.6	0.612

Nurse consultations (number)	207	6.3	7.4	159	5.9	7.4	0.976


Stage	Serum creatinine criteria

1	1.5-1.9 times baseline

OR

≥ 26.5 5 μmol/l (0.3 mg/dl) increase within 48 hoursa

2	2.0-2.9 times baseline

3	≥ 3.0 times baseline

OR

Increase in serum creatinine to ≥ 354 μmol/l (4.0 mg/dl)b

OR

Initiation of renal replacement therapy


Factors	Categories	No. of patients (%)	P value

Gender	Female	465(27.1)	0.301

	Male	1250(72.9)

age		57.5 ± 10.9	<0.001

Past medical history	No	1258(73.4)	0.022

	Yes	457(26.6)

Family history of gastric cancer	No	1431(83.4)	0.431

	Yes	284(16.6)

Location of tumor	Lower third	1086(63.3)	<0.001

	Middle third	281(16.4)

	Upper third	193(11.3)

	Whole stomach	155(9.03)

Eradicative degree of surgery	Utterly	809(47.8)	<0.001

	Relatively	473(27.6)

	Palliative	433(25.2)

Tumor size(mm)	<40	364(21.2)	<0.001

	≥40	1315(78.8)

Stage	I	301(17.5)	<0.001

	II	425(24.8)

	III	497(29.0)

	IV	492(28.7)

Combined evisceration	No	1323(77.1)	<0.001

	Yes	392(22.9)

Histologic grade	Well differentiated	521(30.3)	<0.001

	Moderately differentiated	253(14.8)

	Poorly differentiated	941(54.9)

Depth of invasion	T1	145(8.5)	<0.001

	T2	879(51.3)

	T3	549(32.0)

	T4	142(8.3)

Lymph node status	N0	629(36.7)	<0.001

	N1	717(41.8)

	N2	272(15.9)

	N3	97(5.7)


Method	Algorithm	False positive rate	False negative rate

MEMSAT-SVM	SVM	0.00%	0.44%

MEMSAT3	NN	0.50%	0.50%

SOSUI	Hydrophobicity analysis	0.33%	1.10%

OCTOPUS	NN + HMM	0.00%	2.51%

PHOBIUS	HMM	2.72%	0.44%


	Denmark	Norway	Sweden

TKA

 Mean	146	70	143

 Median	132	53	105

 Range	1–345	1–275	1–527

UKA

 Mean	35	19	30

 Median	29	16	24

 Range	1–85	1–57	1–104


Parameter	HR	95 % CI	P

Disease-free survival: Cox regression model

TNM stage			0.06

 III-IV (vs. I-II)	2.528	1.299–4.921

Tumor differentiation			0.021

 Poor (vs. Well/moderate)	1.785	1.089–2.925

AREG expression			0.168

 Positive (vs. Negative)	1.418	0.863–2.331

AREG/EGFR coexpression			0.587

 Negative (vs. Positive)	0.922	0.687–1.237

Overall survival: Cox regression model

Tumor size			0.485

 T3-4 (vs. T1-2)	1.24	0.677–2.271

TNM stage			0.03

 III-IV (vs. I-II)	2.25	1.081–4.684

Tumor differentiation			0.004

 Poor (vs. Well/moderate)	2.125	1.277–3.537

Resection margins			0.045

 Positive (vs. Negative)	1.84	1.277–3.537

Lymph node metastasis			0.417

 Yes (vs. No)	1.233	0.743–2.048

AREG expression			0.03

 Positive (vs. Negative)	1.822	1.058–3.137


Comparison	CTCs	ctDNA	Exosomes

Origin	Includes apoptotic tumor and viable tumor cells from a primary or metastatic tumor [71, 73].	Includes cfDNA, from the viable tumor cells or from CTCs [17, 219, 221, 224, 225].	Includes DNA, proteins, lipids, RNAs and metabolites and are discharged by all cells including tumor cells [333, 336, 352, 355–357].

Bio-banked samples used for study	Frozen plasma, urine and other biofluids cannot be used for study of CTCs [116].	Frozen plasma, urine and other biofluids can be used for study of cfDNA [116, 260].	Frozen plasma, urine and other biofluids can be used for study of exosomes [260].

Stability	Unstable [114, 116, 117]	Stable [116]	Very stable [334]

Genetic materials	DNA and RNA [117, 122, 123]	DNA [17, 219, 221]	DNA and RNA [355, 357, 359–361]

Analytic Techniques	CellSearch [84, 148–150, 180, 182, 190], Microfluidic [187, 181], SE-iFISH [186], MetaCell [184], Immunofluorescence [181, 185, 188], ScreenCell [185], ISET Test [188, 190] etc.	dPCR [289], CAPP-Seq [293], TAM-Seq [276], ddPCR [290, 307, 308, 310], COLD-PCR [167], Safe-Seq [294], NGS [299, 308–310], BEAMing [291, 292], WGA [297, 298] etc.	Ultracentrifugation [387, 386, 389–391, 393], ExoChip [392], Precipitation [386], Size-based isolation [386], Immunoaffinity-based isolation [386], Microfluidics-based isolation etc [386].

Morphological study and functional study of tumor cells ex vivo	Yes [128, 129, 188, 190, 206, 210, 213, 214]	No	No

Analysis of protein location on tumor cells	Yes [101, 102]	No	No

Identification of mutations	Yes [165, 185, 187]	Yes [306, 319]	Yes [387, 390, 393]

Identification of epigenetic changes	Yes [414, 415]	Yes [322–325]	Yes [357]

Analysis of RNA transcription profiles	Yes [157, 192]	No	Yes [359–361, 367]

Proteomics Analysis	Yes [157]	No	Yes [367, 387, 392]

Analysis tumor heterogeneity	Yes [206]	Yes [332]	No

Use as drug delivery vehicle	No	No	Yes [406, 410]


	Label	Start	Name	Function	References

ldRNA	BSU_misc_RNA_3	119855	ldlJ	Ribosomal protein L10 leader mRNA sequence	26101249

suRNA	BSU_misc_RNA_7	486092	swaO	ATP‐, cyclic di‐AMP‐sensing riboswitch	25086507, 25086509

CDS	BSU04785	528025	cmpA	Factor allowing degradation of SpoIVA by ClpXP	26387458

suRNA	BSU_misc_RNA_65	532642	sncO	ICEBs1 mobile element: conserved small untranslated RNA	20525796, 22505685

suRNA	BSU_misc_RNA_66	559610	sncZ	No identified function: borders undefined	20525796

suRNA	BSU_misc_RNA_8	626446	aswA	Adenine riboswitch	25573585

CDS	BSU09958	1071402	sscA	Spore assembly and germination protein	21670523

CDS	BSU09959	1071613	sscB	Spore assembly and germination protein	21670523

suRNA	BSU_misc_RNA_67	1233405	roxS	Small regulatory RNA (NO regulated)	28436820

CDS	BSU12815	1348356	spoIISC	Three component toxin/antitoxin/antitoxin SpoIISABC, antitoxin C	25039482, 26300872, 27294956

Riboswitch	BSU_misc_RNA_16	1376328	guwA	Guanidinium riboswitch	28212758

Riboswitch	BSU_misc_RNA_68	1395622	swmG	Magnesium riboswitch (modest affinity)	28455443

Riboswitch	BSU_misc_RNA_87	1410633	mnrW	Manganese ion riboswitch	25794618, 25794619

Riboswitch	BSU_misc_RNA_88	1457005	gswA	Riboswitch regulating ptsGHI expression via GlcT binding	15155854, 22750856

suRNA	BSU_misc_RNA_69	1483557	fsrA	Regulatory RNA controlling iron‐dependent metabolism	24576839

suRNA	BSU_misc_RNA_70	1534070	srrA	Small regulatory RNA and messenger RNA (arginine metabolism)	27449348

CDS	BSU14629	1534120	rgpA	Regulator of GapA synthesis	27449348

CDS	BSU15140	1580622	rsmH	16S rRNA m4C1402 methyltransferase	27711192

suRNA	BSU_misc_RNA_89	1780554	surX	sigW‐dependent	23155385

CDS	BSU17845	1916955	yzzP	No identified function, present in some S. pneumoniae strains	27144405

CDS	BSU18978	2069883	bsrE	Type I toxin (BsrE/AsrE)	26940229

suRNA	BSU_misc_RNA_74	2070115	asrE	Small regulatory antitoxin RNA, toxin‐antitoxin type I system (BsrE/AsrE)	26940229

CDS	BSU19749	2146053	yoyG	Putative toxin of a type I toxin family (sporulation operon)	20156992, 21670523

fCDS	BSU20049	2160397	nrdFBc	Phage SP beta nucleoside diphosphate reductase minor subunit (C‐terminus)	23391036

fCDS	BSU20051	2161778	nrdFBn	Phage SP beta nucleoside diphosphate reductase minor subunit (N‐terminus)	23391036

suRNA	BSU_ncRNA_1	2208880	aimX	Small RNA controlling lysogeny of phage SPbeta	28099413

CDS	BSU20850	2208980	aimP	Arbitrium lysis /lysogeny regulatory peptide (GMPRGA)	28099413

CDS	BSU20860	2210154	aimR	Arbitrium peptide sensor regulator	28099413

asRNA	BSU_misc_RNA_90	2219849	apbT	Antisense RNA of Toxin SpbT	24576839

CDS	BSU21000	2219960	spbT	Toxin	24576839

suRNA	BSU_misc_RNA_91	2472880	pswI	Proline T‐box riboswitch upstream of porI	21233158

suRNA	BSU_misc_RNA_82	2773783	surF	Expressed under sporulation conditions	25790031

ldRNA	BSU_misc_RNA_43	2855915	ldlU	Ribosomal protein L21 leader mRNA sequence	27381917

CDS	BSU28475	2910746	lysCB	Beta subunit of aspartokinase II	1980002

ldRNA	BSU_misc_RNA_47	2953550	ldlT	Ribosomal protein L20 leader mRNA sequence	23611891

ldRNA	BSU_misc_RNA_93	3035589	ldsD	Ribosomal protein S4 leader mRNA sequence	23611891

asRNA	BSU_ncRNA_2	3335545	auzJ	Putative antisense RNA for YuzJ putative toxin (toxin I signature)	20156992, 21670523

suRNA	BSU_misc_RNA_94	4169919	mswM	Manganese riboswitch	25794618, 25794619


Top 16 most significant in order	Chemical shift (ppm)	I/II stage of CRC vs healthy controls	Related metabolomic pathway

VIPa	p-valueb	Variations vs HC

Choline	3.19(s)	2.25	0.000	↓	Choline metabolism, Lipid metabolism

Phenylalanine	3.19(m)3.98(dd)	2.251.43	0.0000.004	↓↓	Amino acid metabolism, Phenylalanine metabolism

Asparagine	2.80(dd)	1.90	0.000	↓	Urea metabolism, Amino acid metabolism

Isocitrate	3.98(d)	1.84	0.005	↓	TCA cycle

Cysteine	3.97(dd)3.06(m)	1.841.70	0.0030.000	↓↓	Amino acid metabolism, Glutamate Metabolism, Glutathione Metabolism

Hippurate	3.96(d)	1.84	0.005	↓	Gut microflora metabolism

Dimethyl sulfone	3.138(s)	1.72	0.000	↓	Gut microflora metabolism, Endogenous methanethiol metabolism

Creatinine	3.03(s)4.05(s)	1.701.43	0.0070.003	↓↓	Urea metabolism, Creatinine metabolism

Alanine	1.46(d)	1.67	0.017	↓	Amino acid metabolism, Gluconeogenesis

Methylamine	2.59(s)	1.12	0.018	↓	Gut microflora metabolism, Disulfiram Pathway

Homocysteine	2.14(m)	1.76	0.014	↑	Amino acid metabolism, Methionine metabolism

Glutamine	2.12(m)3.76(t)	1.761.53	0.0010.017	↑↑	Glutaminolysis, TCA cycle

cis-Aconitate	3.43(d)	1.64	0.043	↑	TCA cycle, Glyoxylate, Dicarboxylate metabolism

Acetoacetate	2.27(s)3.43(s)	1.591.64	0.0090.043	↑↑	Fatty acid metabolism, TCA cycle

trans-Aconitate	3.74(s)	1.54	0.019	↑	TCA cycle

Guanidoacetate	3.78(s)	1.53	0.017	↑	Urea metabolism


Characteristic	HIV infected patients	Normal controls

Subject no.	32	35

Age (years, mean ± SD)	34 ± 6	36 ± 6

Male (No, %)	15 (46.9%)	15 (42.9%)

Han Ethnic (No, %)	32 (100%)	35 (100%)

CD4 (cells/μL, mean ± SD)	331 ± 235	N/A

VL [log copies/mL (mean ± SD)]	4.15 ± 1.09	N/A

Time since diagnosis (weeks, mean, range)	65 (1–336)	N/A


Model mechanism	Symbol	Mathematical expressions

First-order decay (n=1)	F1	(1–α)

Second-order decay (n=2)	F2	(1– α)2

Third-order decay (n=3)	F3	0.5 · (1– α)3

Avrami-Erofeev (n=2)	A2	2 · (1– α) · [–ln(1– α)]0.5


Preamble

These recommendations are relevant to all practitioners and organizations communicating the new Canadian Physical Activity Guidelines for Youth. These recommendations should be used to create a clear understanding of the new Canadian Physical Activity Guidelines for Youth and to construct and to deliver messages that promote achievement of the guidelines.

Recommendations

Target Audience	Messages should separately target younger youth (12-14 yrs) and their parents and older youth (15-17 yrs) and their parents.

Clarification Messages	Clarification messages should: a) provide concise and clear descriptions of the guidelines and physical activity, b) define different levels of physical activity intensity (e.g., vigorous, vs. moderate), c) identify physical activity opportunities, d) include information about where to access more information about physical activity, e) indicate that science has evolved since the release of the old guidelines and that the new guidelines reflect latest evidence about physical activity, f) address the semantic differences between the old and new guidelines (e.g., up to 90 minutes vs. at least 60 minutes), and g) provide a wide variety of examples of physical activity – from active living to sport.

Motivational Messages	Motivational messages should emphasize a) parents’ pivotal role in encouraging and supporting their youth’s physical activity, b) a variety of benefits that physical activity offers including emotional, developmental, physical and academic benefits, c) that physical activity can be a collective-social movement that promotes community, active living and the environment, d) the importance of planning physical activity by parents and youth, e) strategies for overcoming barriers to physical activity, and f) empowering youth to choose how they will meet the guidelines.

Examples

60 minutes every day! As a parent, you can help your teen get there.

Move your teen to move more.

Life looks better with physical activity.

Pick a time. Pick a place. Move your teens to move more.

Pick a time. Pick a place. How you want to get active is up to you!

Plan ahead for roadblocks!

Expand your horizons! How you want to get active is up to you!

Channels of Delivery	Messages should be disseminated to parents through websites, mass media campaigns featuring celebrities, magazines and news articles, and smart phone applications.

Messages should be disseminated to youth through websites, promotional materials within their school, public service announcements featuring celebrities, social media, smart phone applications, and community organizations and events.


Gene	Variant	Position	OR	Common/Rare	Domain	Variant domain effect	Effect on AP	Ref

C3	R102G	19:6718387	1.7–2.6	Common	Macroglobulin 1	Decreased binding efficiency of C3b to its inhibitor CFH decreasing CFH’s cofactor activity	Increased AP	[20, 65]

C3	P314L	19:6713262	1.5	Common	Macroglobulin 3	Decreased binding efficiency of C3b to its inhibitor CFH decreasing CFH’s cofactor activity	Increased AP	[65]

C3	K155Q	19:6718146	2.8–3.8	Rare	Macroglobulin 2	Reduces binding to FH and C3b proteolytic cleavage by CFI	Increase C3 convertase production	[59, 65]

CFB	R32Q	6:31914180	0.32	Common	Ba	Reduced affinity for C3b and reduced hemolytic activity	Decrease formation of C3 convertase; reduced AP	[130]

CFB	L9H	6:31914024	0.37	Common	Signal peptide	Affects secretion of CFB	Decrease formation of C3 convertase; reduced AP	[12]

CFH	Y402H	1:196659291	2.45–5.57	Common	Complement control protein 7	Affects binding to GAG heparin sulfate, sialic acid, and C-reactive protein	Reduces ability of CFH to degrade C3: increased AP	[131]

CFH	R1210C	1:196716375	23.11	Rare	Complement control protein 20	Defective binding to C3b, C3d, and heparin	Impaired CFH attachment to host surfaces; reduces AP regulation	[58]

CFH	R53C	1:196642206		Rare	Complement control protein 1	Reduced accelerating activity for AP C3 convertase	Altered CFH-mediated cofactor activity or decay-accelerating activity; increased AP	[63]

CFH	D90G	1:196643011		Rare	Complement control protein 2	Alters CFI cofactor activity	Decreased cofactor-mediated inactivation; increased AP	[63]

CFH	I62V	1:196642233	1.95–2.79	Common	Complement control protein 2	Binds more efficiently to C3b	Enhanced cofactor activity and increased formation of iC3b; reduced AP	[63]

CFH	N1050Y	1:196712596	0.4	Common	Complement control protein 18	Possibly affects GAG and sialic acid binding	Increased AP	[62]

CFHR1/3	CFHR1/3del		0.29	Common	n/a	n/a	Reduces cofactor activity for CFI and inhibits C5 convertase; reduced AP	[13] [132–135]

CFI	G119R	4:110685820	22.2	Rare	Scavenger receptor cysteine-rich	Perturbs interdomain packing and stability of CFI	Diminished ability to degrade C3b; increased formation of C5 convertase; increased AP	[19]

CFI	G188A	4:110682768		Rare	Scavenger receptor cysteine-rich	Perturbs interdomain packing and stability of CFI	Diminished ability to degrade C3b; increased formation of C5 convertase; increased AP	[19]

C9	P167S	5:39331894	2.2	Rare	Membrane attack complex/perforin	Alters oligomerization and possibly inhibits C9's lytic activity	Affects binding with CD59; alters pore formation	[59]


Alcohol consumption	MTHFR genotype	Cases n (%)	Controls n (%)	Age-adjusted OR (95% CI)

Low	CC	3 (8)	29 (20)	1.00 (ref)

Low	CT + TT	5 (14)	39 (27)	1.25 (0.28–5.65)

High	CC	14 (38)	31 (21)	4.43 (1.15–17.05)

High	CT + TT	15 (41)	47 (32)	3.10 (0.83–11.65)

p-interaction (multiplicative)			0.51

p-interaction (additive)			0.58


	Strain detected

Pathogen	Only by BC	Only by SeptiFast	Both methods

S.aureus (MSSA)	0	3	3

S.aureus (MRSA)	2	0	4

S.pneumoniae	0	1	0

Streptococcus spp.	0	2	1

Enterococcus faecalis	0	1	0

Enterococcus faecium	2	0	0

Enterobacter aerogenes/cloacae	0	3	1

Escherichia coli	0	3	9

Klebsiella pneumoniae/oxytoca	1	5	1

Pseudomonas aeruginosa	1	4	1

Candida albicans	0	1	0

Candida tropicalis	0	1	1

Sub-total	6	24	21

Not detectable by SeptiFast	5	0	0

Total	11	24	21


Year	Authors	Age, gender	Concurrent malignancy (location)	Past history of recurrence	Diagnostic modality

2015	Jerraya H, et al.	59, F	Insulinoma (pancreas)	NA	NA

2015	Jung SY, et al.	11, F	Insulinoma (pancreas)	Non	US, CT, MRI

2009	Wheeler YY, et al.	62, M	Renal cell carcinoma (right kidney)	Non	CECT

2015	Present case	23, M	SCS (abdominal)	Abdominal	US, CECT, MRI


 	LOO AUC (SE)	Sensitivity	Specificity	Median number of peaks per LOO iteration	Mean number of peaks per LOO iteration (SD)

Lymph node status

 Negative vs Positive	0.95 (0.03)	73.9	91.7	1	1 (0)

Histological subtype

 Squamous ca. vs adenoca.	0.88 (0.05)	88.2	59.0	1	1 (0)

 Squamous ca. vs adsq ca.	0.85 (0.06)	84.6	100	4	3.8 (0.9)

 Adenoca. vs adsq ca.	0.94 (0.06)	94.1	100	1	0.9 (0.3)

LVSI

 Negative vs Positive	0.81 (0.06)	78.1	73.1	1	1 (0)

Recurrence

 Negative vs Positive	0.92 (0.04)	79.2	90.0	3	3 (0)


	Annual expenses ($)

Annual cost of mobile health clinic	565,700

Total annual visits	4,848

Total visits discounted by 20%	3,878

Cost per visit	117

Cost of preventable emergency department visit [9]	923

Cost avoided per mobile clinic visit	806

Annual projected costs avoided	3,125,668


Primer	Gene	Sequence	Fragment size (bp)

rpoB-FS		TGGTCCGCTTGCACGAGGGTCAGA

	rpoB		758

rpoB-RS		CAGGAAGGGAATCATCGCGG

katG-FS		TGCAGATGGGGCTGATCTACG

	katG	ACCCATGTCTCGGTGGATCAG	596

katG-RS

inhA-FS		ACATACCTGCTGCGCAAT

	inhA	TCACATTCGACGCCAAAC	400

inhA-RS


Toxo DB typea	No. of isolates	Designation

9, (Chinese1)	1	TgDgCo4

10 (Type I)	2	TgCtCo 2, 7

14	6	TgDgCo9,12,15,18; TgCkCo2;TgCtco14

18	3	TgCtCo 12, 13; TgDgCo3

23	1	TgDgCo19

28	2	TgCtCo 1; TgCkCo5

29	5	TgDgCo1,2,10,20; TgCkCo20

38	13	TgCkCo6,8,10,12,13,15,21,23,24; TgCtCo 4,10,11; TgDgCo17

40	1	TgCtCo5x

44	3	TgDgCo5,6,11

46	3	TgDgCo8,14,16

61	2	TgCtCo 5,6

62	2	TgCtCo3,9

79	1	TgDgCo13

101	1	TgCtCo15

122	1	TgDgCo7

128	1	TgCtCo8

178	1	TgCkCo4

179	2	TgCkCo17,22

188	1	TgCkCo9


Region-based test result	Truth

	True HA	True H0	Total

p-value < Threshold: reject null hypothesis	A	C	A + C

p-value ≥ Threshold: do not reject null hypothesis	B	D	B + D

Total	A + B	C + D


Items	Cu NPs	Cu MPs

Shape	Spherical	Spherical

Primary sizea	32.7 ± 10.5 nm	25.3 ± 6.6 μm

Hydrodynamic size (nm)b	pH 1.5	n.a	n.a

pH 6.5	516 ± 116.9	n.a

pH 7.8	334 ± 128.3	n.a

Surface area (m2/g)c	14.7	0.16

Zeta potential (mV)d	pH 1.5	25.5 ± 0.8	n.a

pH 6.5	1.32 ± 1.2	n.a

pH 7.8	−6.2 ± 0.2	n.a


 	β intercept (standardised coefficient)	P value

Height	0.094	0.48

Weight	0.003	0.98

Fat%	0.058	0.53

Physical activity	0.215	<0.01

Age of onset of diabetes	0.16	0.09

Duration of diabetes	−0.046	0.56

HbA1c	−0.451	<0.01

Insulin dose	0.20	0.07

Calcium intake	0.05	0.53

25(OH) vitamin D3	−0.003	0.964

Alkaline phosphatase	−0.19	0.09

PTH 	−0.026	0.71

IGF-1	0.31	<0.01

Testosterone	0.14	0.12

SHBG	0.11	0.24


Parameter	Meaning	Value

kphr	Phosphorylation of RsbR	0.1 / 1

kdpr	Dephosphorylation of RsbR-P	0.06

kphs	Phosphorylation of RsbS	0.4

kdps	Dephosphorylation of RsbS-P	1


	Sex	Age	Pituitary MRI	Internal carotid RMI	Other characteristics	Molecular studies	References

1	N	N	Not specified (except for normal posterior pituitary).	Absence of ICA and carotid canal.	Not specified.	NP	[14]

2	M	18 m	Pituitary hypoplasia.	Anomaly of right ICA.	TSH, GH, ACTH deficiency. Central diabetes insipidus. Possible hypogonadism.	NP	[13]

3	F	5 m	Absence of anterior pituitary and ectopic pituitary posterior lobe.	Absence of right common carotid artery, right ICA, right anterior cerebral artery.	TSH, ACTH and GH deficiency. No evidence of diabetes insipidus. Genitalia were normal. Single central maxillary incisor.	NP	[7]

4	M	23 year	Absence of anterior pituitary and ectopic pituitary posterior lobe.	Absence of right ICA and carotid canal and A1 segment of the right anterior cerebral artery.	Congenital microphthalmia with cataract and coloboma of the right eye, encephalocele. Hormonal substitution treatments not specified.	NP	[5]

5	M	37 year	Absence of anterior pituitary.	Hypoplasia of right ICA and carotid canal.	Amblyopia of the left eye caused by an optic nerve coloboma, encephalocele. Hormonal substitution treatments not specified.	NP	[5]

6	F	29 year	Pituitary hypoplasia and ectopic pituitary posterior lobe.	Absence of right ICA, carotid canal, and A1 segment of the right anterior cerebral artery.	TSH, ACTH, and GH deficiency. No evidence of diabetes insipidus. Hypogonadism. Chiari I malformation with syringomyelia.	NP	[9]

7	M	5 year	Absence of anterior pituitary and ectopic pituitary posterior lobe.	Absence of left ICA and carotid canal, A1 segment of the left anterior cerebral artery and the anterior communicating artery.	Retrognathia, microphallus, and cryptorchidism. TSH, ACTH, GH deficiency, but no evidence of diabetes insipidus. Possibile hypogonadism.	NP	[10]

8	M	11 year	Pituitary hypoplasia	Absence of left ICA and carotid canal; hypoplasia of A1 segment of left anterior cerebral artery	TSH, ACTH, GH deficiency. Central diabetes insipidus. Microphallus with possible hypogonadism.	NP	[6]

9	F	10 year	Hypoplastic anterior pituitary, flat sella turcica, absent pituitary stalk	Agenesis of the left ICA and the left carotid canal	GH, TSH, gonadotropin deficiency. No evidence of diabetes insipidus. Born out of a consanguineous marriage.	No HESX1, LHX4, OTX2 mutations	[8]

10	F	7 month	Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity	Absence of the left ICA	Desaturation episodes, recurrent respiratory infections. Short hands and feet. GH, ACTH and TSH deficiency.	17q24.2 deletion	[3]

11	F	2 year	Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity	Absence of the right ICA	GH, TSH, and gonadotropin deficiency. No clinical evidence of diabetes insipidus.	NP	[11]

12	M	3 week	Absence of anterior pituitary with ectopic posterior pituitary	Absence of the left ICA and carotid canal	GH, TSH, ACTH and gonadotropin deficiency. Microphallus.	NP	[12]

13	M	17 year	Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity	Agenesis of the left ICA	GH deficiency. No other pituitary deficiencies. No clinical evidence of diabetes insipidus.	Normal array-CGH	Our case


#	SET I (8-week-old)	Summary

1	Control diet (CD)	Peliosis, nuclear dysplasia and nuclear retreat.

2	CD + Quercetin	Small & large lymphoplasmacytic clusters.

3	CD + δ-Tocotrienol	Large lymphoplasmacytic (LP) cluster, Councilman body.

4	CD + Dexamethasone	Councilman body, nuclear retreat and dysplasia, microvesicular steatosis, large lymphoplasmacytic (LP) cluster, closed sinusoids, cytoplasmic condensation.

	SET II (46-week-old)	Summary

5	Control diet (CD)	LP clusters, nuclear Retreat and dysplasia, microvesicular steatosis.

6	CD + Quercetin	Coucilman body, nuclear dysplasia and nuclear retreat.

7	CD + δ-Tocotrienol	Small & large Lymphoplasmacytic clusters.

8	CD + Dexamethasone	Small LP cluster, Councilman body, nuclear Retreat and dysplasia cytoplasmic condensation.


Acronym	Description	Source

GDP	Gross Domestic Product per capita (PPS$), i.e. a measure of the economic activity and of the wealth of a country.	(1)

Real GDP Growth rate	The growth rate of the GDP in terms of volume (%), values determined by the prices of the previous year, and thus computed volume changes are imposed on the level of a reference year so that price movements will not inflate the growth rate.	(2)

Government Debt	General government gross debt (% of GDP, million EUR).	(1)

U	Unemployment rate (%), i.e. the percentage of unemployed people in the active population.	(3)


Variable	Mean	95% CI

Children seen per day	1.8	1.8-1.9

Time spent on seeing children (hrs)/day	0.4	20.9-21.1

No of Health education activities/day	2.5	2.3-2.6

Time spent on IEC (hrs)	0.2	11.4-12.8

Follow-ups/day	**2.6	2.4-2.8

Hours on follow-up/child	1.7	1.5-1.8

Total hours spent on CCMm activities/day	*4.8	3.9-5.3


Study	Cell type	Treatment	Time points	Array

Expression profiling studies on 3T3-L1 cell line

Guo et al. 2000 [14]	3T3-L1	DMI	0h, 6d	18k mouse cDNA filter arrays

Soukas et al. 2000 [15]	3T3-L1	DMI	PC,0h,6h,12h,24h,2d,3d, 4d, 7d,28d	Affymetrix mouse Mu11k

Ross et al. 2002 [16]	3T3-L1	DMI|DMI+Wnt-1↑	0h, 16h, 32h, 2d, d14	Affymetrix mouse U74A

Burton et al. 2002 [17]	3T3-L1	DMI	0h,2h,8h,16h,24h	AffymetrixmouseMu11k

Burton et al. 2004 [18]	3T3-L1	DMI|DMI+TSA	0h,2h,8h,16h,24h,d2,d4	Affymetrix mouse U74A

Jessen at al. 2002 [19]	3T3-L1	DMI	0h, 1d, 4d, 7d	Affymetrix Mu11kB| U74Av2

Gerhold et al. 2002 [20]	3T3-L1	DMI+TZD|nTZD	0h, PA 6hT, PA 48hT, AD 6hT, AD 48hT	4k Affymetrix mouse mu6800

Hsiao et al. 2004 [21]	3T3-L1	TZDs	AD 24hT	Affymetrix mouse U74Av2

Hackl et al. 2005 [22]	3T3-L1	DMI	PC,0h,6h,12h,24h,2d,3d,4d,7d,14d	27K mouse cDNA microarray

Liu et al. 2005 [23]	3T3-L1	DMI|DI		Affymetrix mouse MOE430A

Pantoja et al. 2005 [24]	3T3-L1	D↔M I| M↔D I		38 k MEEBO microarray oligo set

Adipogenesis expression studies on other mouse cell models including over-expression and knock out strategies

Huo et al. 2006 [25]	3T3-F442A	GH		Affymetrix mouse U74Av2

Akerblad et al. 2005 [26]	NIH-3T3	Ebf1↑|Pparg↑		Affymetrix mouse U74Av2

Baudry et al. 2006 [27]	PKB-/-MEF			22k Affy mouse MOE430A

Christian et al. 2005 [28]	RIPKO			Affymetrix mouse MOE430 2.0

Otto TC et al. 2007 [29]	C3H10T1/2	Bmp4↑		Affymetrix mouse MOE430 2.0

Tseng et al. 2005 [30]	IRSKO PA			Affymetrix mouse U74Av2

Timmons et al. 2007 [31]	wPA, bPA		0d, 1d, 4d, 8d	Affymetrix mouse U74Av2

Adipogenesis of human cell models

Hung et al. 2004 [32]	hMSC	DMI	0h,3d	8k human Universochip

Sekiya et al. 2004 [33]	hMSC		0h,1d,7d,14d,21d	12k Affymetrix human U95Av2

Nakamura et al. 2003 [34]	hMSC			3.4k focused cDNA microarray

Scheideler et al. 2008 [35]	hMADS	DMI+ROS	PC,-2d, 0h, 8h, 1d, 2d, 5d, 10d, 15d	30k human spotted oligo array

Urs et al. 2004 [36]	PA|AD			19K human cDNA microarray


Characteristic	Crude odds ratios with 95% confidence interval	Adjusted odds ratios with 95% confidence interval

Age above 25 years	1.65 (1.33-2.04)*	.74 (.54-1.02)

Age 24 years & below -Ref

Income 5001 NPR or above	.85 (.71-1.00)	1.30 (1.04-1.62)**

5000 NPR or less/month- Ref

Education secondary or higher	.35 (.27-.44)*	.41 (.31-.55)*

Uneducated or Primary level- Ref

Hindu religion	.15 (.09-.24)*	.09 (.05-.18)*

Non-Hindu - Ref

≥ 3 Children	2.48 (1.93-3.19)*	2.05 (1.56-2.71)*

≤ 2 Children - Ref

Desire more children	.78 (.62-.99)**	.72 (.55-.95)**

No more desire - Ref

Men attempt domestic violence	1.87 (1.56-2.24)*	1.29 (1.04-1.61)**

Not attempt - Ref

Associated factors for male decision making to contraceptive use (N = 2394)

Age above 25 years	1.63 (1.30-2.05)*	1.57 (1.15-2.14)**

Age 24 years & below -Ref

Income 5001 NPR or above	1.09 (.92-1.30)	.67 (.54-.82)*

5000 NPR or less/month- Ref

Education secondary or higher	4.54 (3.53-5.84)*	4.11 (3.12 - 5.42)*

Uneducated or Primary level- Ref

Hindu religion	2.32 (1.70-3.16)*	1.43 (.95-2.16)

Non-Hindu - Ref

Non-Indigenous ethnicity	2.40 (1.85 -3.10)*	1.49 (1.06-2.10)**

Indigenous ethnicity - Ref

≥ 3 Children	.67 (.54-.82)*	.70 (.55-.88)**

≤ 2 Children - Ref

Desire more children	.64 (.50-.82)*	.66 (.50-.87)**

No more desire - Ref

Men attempt domestic violence	.62 (.52-.73)*	.83 (.68-1.02)

Not attempt - Ref


		cELISA

		Positive	Negative	Total

T. equi (A)

 IFAT	Positive	48	7	55

Negative	10	43	53

Total	58	50	108

B. caballi (B)

 IFAT	Positive	4	16	20

Negative	3	85	88

Total	7	101	108


	Aniso nucleosis (±)	Large cherry red nucleoli (±)	Small cherry red nucleoli (±)	Large cells (±)	Mesothelial like sheets (±)	3 dimensional cluster (±)

Malignant	7/4	9/2	2/9	4/7	5/6	11/0

Non-malignant	17/26	1/42	20/23	39/4	21/22	NA

p value	*	0.0252	*	*	*	<0.0001


Review	Professional background (code used in the quotes)	Knowledge of the clinical area	DTA-related knowledge	Systematic review methods	Academic role within university	Policy- making experience

Galactomannan detection for invasive aspergillosis in immune-compromized patients	Hematologist (H1)	Yes	Good	Some	Yes	Yes

 	Hematologist (H2)	Yes	Good	Some	Yes	Yes

Policy maker (PM1)	No	Some	Good	Yes	Yes

Systematic reviewer (SR1)	No	Little	Good	Yes	No

Health economist (HE1)	No	Little	Good	No	No

Systematic reviewer (SR2)	No	Good	Good	Yes	Yes

Physical examination for lumbar radiculopathy due to disc herniation in patients with low back pain	GP (GP1)	Yes	Little	Little	No	No

GP (GP2)	Yes	Little	Little	No	No

Physiotherapist (PH1)	Yes	Little	Good	Yes	No

GP (GP3)	Yes	Good	Good	No	Yes

Physiotherapist (PH2)	Yes	Good	Good	Yes	Yes

Policy maker (PM2)	Yes	Good	Good	Yes	Yes

 	Policy maker (PM3)	No	Some	Good	Yes	Yes

MRI versus CT for detection of acute vascular lesions in patients presenting with stroke symptoms	Radiologist (R1)	Yes	Little	Little	No	No

Systematic reviewer (SR3)	No	Little	Some	No	No

Health economist (HE2)	No	Good	Good	No	Yes

Health economist (HE3)	No	Little	Some	No	No

Systematic reviewer (SR4)	No	Little	Good	Yes	No

Systematic reviewer (SR5)	No	Good	Good	Yes	No

Systematic reviewer (SR6)	Yes	Some	Good	Yes	No

Policy maker (PM4)	Yes	Good	Good	Yes	Yes


Question	Session	n	≥ 4 (%)

I believe the work in this session is relevant for professional nurses	1	52	98

2	49	84

I believe the work in this session is relevant for me as an individual	1	52	96

2	49	88

Overall I am satisfied with this session	1	49	94

2	49	76


Algorithms	MAPE (%)	RMSPE (%)	Error of RUL prediction

INW–ESN (dynamica)	9.32	7.27	23 min

INW–ESN (static)	17.14	14.64	Failed

RNN (dynamica)	16.38	13.44	138 min

ESN (dynamica)	14.60	10.87	161 min

ELM (static)	13.91	9.48	69 min


PCR	Forward (F) primer/reverse (R) primer (5′–3′)	PCR mixture	Cycling conditions

rDNA21	Nest1 F: GCTGTAGGTGAACCTGCAGCAGCTGGATCATT	50 μL reaction; 5 μL DNA from filter papers (or 5 μL N1), 25 μL QIAGEN HotStar Taq Master Mix (QIAGEN), 0.3 μM primers	95°C, 15 minutes

Nest1 R: GCGGGTAGTCCTGCCAAACACTCAGGTCTG	35–40 cycles

Nest2 F: GCAGCTGGATCATTTTCC	94°C, 0.5 minutes

Nest2 R: AACACTCAGGTCTGTAAAC	58°C, 0.5 minutes

	72°C, 1.5 minutes

	60°C, 1 minutes

	75°C, 10 minutes

ITS222	F: GGGAGAAGCTCTATTGTG	25 μL reaction; 1 μL N2 product from rDNA PCR, KCl buffer (15 mM MgCl2, Bioline, London, UK), 2 mM deoxynucleotide triphosphates, 0.4 μM primers, 1U Taq polymerase	94°C, 2 minutes

R: ACACTCAGGTCTGTAAAC	40 cycles

	94°C, 20 seconds

	53°C, 30 seconds

	72°C, 1 minutes

	72°C, 10 minutes

kDNA6	Nest1 F: C/GA/GTA/GCAGAAAC/TCCCGTTCA	50 μL reaction; 5 μL DNA from filter papers (OR 5 μL N1), 25 μL QIAGEN HotStar Taq Master Mix, 0.3 μM primers	95°C, 15 minutes

Nest1 R: ATTTTTCG/CGA/TTTT/CGCAGAACG	30 cycles at

Nest2 F: ACTGGGGGTTGGTGTAAAATAG	94°C, 1 minutes

Nest2 R: TCGCAGAACGCCCCT	55°C, 1 minutes

	72°C, 1.5 minutes

	60°C, 1 minutes

	75°C,10 minutes


Items_Details	Number of genes	Adjusted p-Valuea	Genes

Signaling pathways

Focal adhesion	27	1.8E-08	ITGA1, MAPK1, comP, ITGA6, ERBB2, LAMA2, CCND2, BCAR1, DIAPH1, PTEN, ITGA2, SPP1, ACTB, LAMC1, CAPN2, COL4A1, EGFR, VAV2, THBS4, ITGA9, THBS2, PTK2, PIK3CG, VEGFA, fn1, PPP1CB, VAV3

Regulation of actin cytoskeleton	27	3.5E-08	PIP4K2A, ITGA1, MAPK1, ARPC2, ITGA6, ITGB2, ARPC1B, F2R, BCAR1, DIAPH1, GNA12, ITGA2, NCKAP1L, GSN, ACTB, TMSB4X, EGFR, VAV2, ITGA9, CD14, PTK2, Kras, BAIAP2, PIK3CG, fn1, PPP1CB, VAV3

ECM-receptor interaction	14	5.8E-06	ITGA1, comP, ITGA6, LAMA2, ITGA2, GP1BB, SPP1, LAMC1, COL4A1, THBS4, ITGA9, THBS2, AGRN, fn1

Adherens junction	12	2.7E-05	MAPK1, PARD3, CTNNA3, ACP1, ERBB2, PTPRJ, ACTB, EGFR, BAIAP2, CREBBP, SORBS1, PVRL3

Metabolic pathways

Valine, leucine and isoleucine degradation	12	2.3E-07	ALDH3A2, BCAT1, OXCT1, EHHADH, IVD, BCKDHB, ECHS1, ACADSB, HADHA, PCCB, AUH, ALDH2

Lysine degradation	9	0.0002	MLL5, ALDH3A2, EHHADH, NSD1, WHSC1L1, ECHS1, HADHA, setmar, ALDH2

Purine metabolism	16	0.00033	NUDT2, Pgm2, GMPR2, POLR2G, ENPP1, RRM2B, FHIT, GUCY1A3, ADA, NT5C2, NME6, PGM1, PRPS2, ATIC, NT5E, POLR3E

beta-Alanine metabolism	6	0.00088	ALDH3A2, EHHADH, ECHS1, CARNS1, HADHA, ALDH2

Arginine and proline metabolism	8	0.0014	ALDH3A2, ACY1, P4HA1, GLUD1, CARNS1, AMD1, ALDH4A1, ALDH2

Fatty acid metabolism	7	0.0014	ALDH3A2, EHHADH, ECHS1, ACADSB, ACSL4, HADHA, ALDH2

Cellular processes

Phagosome	21	9.2E-08	comP, CTSS, ATP6V1C1, ITGB2, ITGA2, PIK3C3, ACTB, CYBB, CYBA, TFRC, THBS4, CD14, THBS2, NCF4, NCF2, DYNC1I2, EEA1, FCGR2B, MRC1, TUBA8, TUBA4A

Protein processing in endoplasmic reticulum	21	7E-07	nsfl1c, BAG2, UBE4B, PARK2, SAR1B, HSPH1, SEC24D, DNAJC1, CAPN2, DDOST, BCAP31, HSPA2, PDIA3, CUL1, UBE2D4, HERPUD1, EDEM2, DNAJA1, DERL1, CKAP4, TUSC3

mRNA surveillance pathway	13	0.000016	SAP18, PPP2R5A, CPSF6, CLP1, PPP2R2A, PAPOLA, PAPOLB, PPP2CB, Fip1l1, ETF1, HBS1L, CPSF3, CSTF2T

Endocytosis	20	3.61E-05	RAB11FIP5, PARD3, KIT, F2R, DNM2, EHD1, RABEP1, ARRB2, GRK5, DNM1L, FOLR1, EGFR, TFRC, HSPA2, WWP1, ZFYVE16, SMAP2, EEA1, epn1, FAM125B


		N	Zinc concentration	N	Height for age z score (mean ± sd)

Cuba	STH uninfected	160	112.55 (88.3–136.0) a	1251	0.11 ± 0.97

	STH infected	70	113.35 (94.4–143.7) a	117	−0.31 ± 1.16

Cambodia	STH uninfected	1239	7.74 ± 1.70 b	1450	−1.81 ± 1.05

	STH infected	254	7.52 ± 1.70 b	296	−1.84 ± 1.09


Studies	Dystrophin IHC staining using FFPE muscle sections

Rod domain (DYS1)	C-terminus (DYS2)	N-terminus (DYS3)

Present study	Successful	Successful	Unsuccessful

Hoshino et al. 2000 [17]	Successful	Successful	Unsuccessful

Sheriffs et al. 2001 [18]	Successful	Successful	Successful

Sajid et al. 2010 [19]	Not performed	Successful	Not performed


Block 1	SNPs		Frequency of the haplotype

	rs915941	rs915942	population	Group A	Group B	Males	Females	Males	Group B

						Group A	Group A	Group B	Females

Haplotypes	A	G	0.880	0.890	0.870	-	0.870	0.878	0.871

C	A	0.119	0.110	0.124	-	0.120	0.122	0.126

Block 2	SNPs					Frequency of the haplotype

	rs2071429	rs2230037	rs4898389	rs5986877	rs7879049	Population (0.64)	Group A (0.73)	Group B (0.77)	Males Group A (N/R)	Females Group A (0.77)	Males Group B (0.76)	Females Group B (0.48)

Haplotypes	A	G	A	C	A	0.545	0.553	0.540	0.475	0.540	0.585	0.516

	G	A	G	G	G	0.402	0.394	0.407	0.475	0.365	0.364	0.431

	G	G	G	G	A	0.034	0.033	0.034	0.013	0.041	0.028	0.038


	Fatigue	Abdominal complaints	Musculo- skeletal complaints	Weight changes	Itch

Alkaline Phosphatase (AF)	x	x		x

Alanine aminotransferase (ALAT)	x	x		x	x

Amylase		x		x

Anti-endomysium		x		x

Aspartate aminotransferase (ASAT)	x	x		x

Bilirubin					x

Erythrocyte sedimentation rate (ESR)	x	x	x	x	x

Carbohydrate-deficient transferrin (CDT)	x	x		x	x

Creatinin kinase (CK)			x

Creatinin	x	x	x	x	x

C-reactive protein (CRP)		x

Differentiated leukocyte count	x	x		x	x

Eosinophils					x

Ferritin	x	x	x	x

Gamma glutamyl transferase (GGT)	x	x		x	x

Glucose	x	x	x	x	x

Haemoglobin (Hb)	x	x	x	x	x

Potassium (K)	x		x

Latex fixation test			x

Lactate dehydrogenase (LDH)	x			x

Leukocyte count	x	x		x	x

Monosticon	x

Total IgE		x			x

Thyroid stimulating hormone (TSH)	x	x	x	x	x

Transferrin saturation (TS)	x	x	x	x

Urea					x

Uric acid			x

Total number of tests	17	18	11	17	14


Variable	Single etiologic agent(n = 126)	Multiple etiologic agents(n = 153)	P-value

Gram-positive cocci

Aerobic

 Staphylococcus aureus

Methicillin-susceptible S. aureus	27 (21.4)	15 (9.8)	0.007*

Methicillin-resistant S. aureus	20 (15.9)	34 (22.2)	0.182

 Coagulase-negative Staphylococcus	2 (1.6)	11 (7.2)	0.042*

 Streptococcus

Beta-hemolytic (Group A)	13 (10.3)	24 (15.7)	0.188

Beta-hemolytic (Group B)	2 (1.6)	4 (2.6)	0.693

Non-group A or B	-	2 (0.7)	-

S. viridans	2(1.6)	36 (23.5)	<0.001*

 Enterococcus faecalis	1(0.8)	45 (29.4)	<0.001*

Anaerobic

 Peptostreptococcus	-	38 (13.6)	-

Gram-positive rods

Aerobic

 Corynebacterium	-	8 (2.9)	-

Anaerobic

 Clostridium spp.	-	5 (1.8)	-

Gram negative rods

Aerobic

 Acinetobacter baumannii	3 (2.4)	20 (13.1)	0.001*

 Aeromonas spp.	11 (8.7)	11 (7.2)	0.635

 Citrobacter spp.	2 (1.6)	9 (5.9)	0.119

 E.coli.	2 (1.6)	35 (22.9)	<0.001*

 Enterobacter spp.	1 (0.8)	19 (12.4)	<0.001*

 Klebsiella pneumoniae	13 (10.3)	28 (18.3)	0.061

 Pseudomonas aeruginosa	3 (2.4)	16 (10.5)	0.008*

 Vibrio spp.	21 (17.5)	-	-

 Eikenella corrodens	-	4 (2.6)	-

 Klebsiella oxytoca	-	3 (2.0)	-

 Proteus mirabillis	-	23 (15.0)	-

 Serratia marcescens	-	7 (4.6)	-

 Other gram negative rods	1 (0.8)	15 (9.2)	0.002*

Anaerobic

 Prevotella spp.	2 (1.6)	10 (6.5)	0.071

 Bacteroides fragilis	-	15 (9.8)	-

 Fusobacterium	-	1 (0.7)	-

 Veillonella	-	3 (2.0)	-

Fungus	-	6 (3.9)	-


Formulation	Aromatic Content in Polymer (%)	EE (%)	LC (%)

Cur-Nano1	0	61.3 ± 0.5	6.8 ± 0.1

Cur-Nano2	25	61.3 ± 0.1	6.8 ± 0.0

Cur-Nano3	100	113.8 ± 3.4	12.6 ± 0.4


Laboratory ID	Laboratory type	Correct diagnosis

All Specimens, n (%)	Smear-Positive Specimens, n (%)	Smear-Negative Specimens, n (%)

1	Network	3 (42.9)	2 (33.3)	1 (100)

2	Network	7 (100)	6 (100)	1 (100)

3	Standalone	1 (14.3)	0 (0)	1 (100)

4	Standalone	1 (14.3)	0 (0)	1 (100)

5	Network	1 (14.3)	0 (0)	1 (100)

6	Standalone	6 (85.7)	6 (100)	0 (0)

7	Network	7 (100)	6 (100)	1 (100)

Indus Hospital	N/A	7 (100)	6 (100)	1 (100)


Reference/reference number	Surrogate product	Countries	Study population	Method

Green [59]	Female condom, foaming tablets, contraceptive sponge, Delfen foam, film and gel	Uganda	131 women; 21 men	Qual

Jones [33]	Astroglide Silken Secret (high-viscosity gel), KY Jelly (low-viscosity gel), Lubrin (suppository)	Zambia	301 women	Quant

Martin [15]	Gel	Thailand	23 women; 28 men	Qual

Montgomery [20]	Gel	South Africa, Tanzania, Uganda, Zambia	45 couples	Qual

Pool [48]	Female condom, foaming tablets, contraceptive sponge, Delfen foam, film and gel	Uganda	138 women; 42 men	Qual

Salter [43]	Gel	Malawi	1686 women; 21 men	Mixed

Tanner [21]	Silken Secret vaginal moisturizer	USA	40 women	Qual

van der Straten [61]	Ring	South Africa, Tanzania	157 women; 19 men	Qual

Weeks [74]	Vaginal moisturizer	USA	546 women interviewed/surveyed; 94 participating in surrogate trial	Mixed


Research Authors (Year)	Purpose	Characteristics	Outcomes

Alwan et al. [110] (2006)	Fall detection	The authors used dummies of humans to simulate original fall events. The experimental tests of falls were performed on concrete floors. A dummy was used to emulate the scenario of a person falling while attempting to get out of a chair. Another dummy was used to emulate the scenario of a person falling with upright position. The experiments were repeated three times with the same dummies.	100% accuracy.

Lombardi et al. [111] (2015)	Movement detection	A data model was proposed for storing and processing floor data. The proposed approach focused on estimating the center of floor pressure based on the widely used biomechanical concept of ground reaction force. Some practical tests on a real sensing floor prototype were attempted. The novel approach outperformed the traditional background subtraction schemas for the correct detection and tracking of people.	97% accuracy.

Serra et al. [112] (2014)	Footstep recognition	An easy-to-install and unobtrusive smart flooring system was proposed based on piezoelectric polymer floor sensors. The smart flooring system was utilized for efficient human footsteps recognition based on the Pearson product–moment correlation coefficient between the testing and reference signals for similarity calculation.	99% accuracy.


	LDA	SVM (Linear)

Accuracy	Precision	Recall	Accuracy	Precision	Recall

Forehead_axis + Mouth_axis	77.8	76.9	66.7	77.8	76.9	66.7

Forehead_axis + Mouth_region	66.7	46.2	54.6	63.9	46.2	50.0

Forehead_region + Mouth_axis	88.9	92.3	80.0	88.9	92.3	80.0

Forehead_region + Mouth_region	75.0	85.7	63.2	77.8	84.6	64.7


Species	No tested	No of positive humans, buffaloes and a lion (Prevalence)

		RBPT	BAPA	Riv.T	95 % CI	TITER

		No	% positive	No	%Positive	No	% positive

Humans	340	5	1.5	2	0.6	2	0.6	0.1, 2.1	1:200*

Buffaloes	38	4	10.5	3	7.9	3	7.9	1.7, 21.4	1:200*

Lion	2	1	1/2	1	1/2	1	1/2		1:200*

Zebra	2	0	0	0		0	0


Characteristic	Value

Age, years

 Mean ± SD 	58.2 ± 13.6

 Range	30–92

Sex, % (n)

 Male	78.1 (25)

 Female	21.9 (7)

Race/ethnicity % (n)

 Caucasian/white	59.4 (19)

 African-American/black	31.3 (10)

 Asian/Pacific Islander	9.4 (3)

Marital status, % (n)

 Married	28.1 (9)

 Single	40.6 (13)

 Other (widowed/divorced)	31.3 (10)

Smoking

History of smoking, % (n)	75.0 (24)

Pack years, mean ± SD	21.0 ± 20.7

History of hypertension, % (n)	71.9 (23)

Creatinine on admission (g/dL), mean ± SD	1.9 ± 1.7

Etiology of heart failure, % (n)

 Ischemic	28.1 (9)

 Idiopathic	65.6 (21)

 Unknown/other	6.3 (2)

Ejection fraction <40%, % (n)	71.9 (23)

ACEi/ARB use—study end, % (n)	62.5 (20)

Beta blocker use—study end, % (n)	78.1 (25)

High-risk diagnoses for the elderly scale

 Low (0) = 9.5% chance dying in 1 year	0 (0)

 Intermediate (1-2) = 31% chance	53.1 (17)

 High risk (3–5) = 46% chance	31.3 (10)

 Very high risk (≥6) = 74% chance	15.6 (5)

Length of hospital stay, days

 Mean ± SD	9.5 ± 9.9

 Median	6.5

 Range	1–41

Physical therapy—in hospital, % (n)	34.4 (11)

LVAD received during study admission, % (n)	6.3 (2)

Discharged with physical therapy, occupational therapy, or home health, % (n)	40.6 (13)

Cardiac events—90 days after discharge, % (n)

 Cardiac readmission	34.4 (11)

 Heart transplant 	3.1 (1)

 Mortality	9.4 (3)


	MMQL-UK (PF) component

MMQL-UK (CF) component	Physical Appearance	School	Social Functioning	Emotional Functioning	Physical Functioning

Physical Appearance	0.51**	0.05	0.20**	0.25**	0.12**

School	0.13**	0.56**	0.22*	0.14**	0.21**

Social Functioning	0.14**	0.10*	0.31**	0.23**	0.18**

Emotional Functioning	0.35**	0.20**	0.26**	0.38**	0.25**

Physical Activities	0.33**	0.25**	0.21**	0.27**	0.61**


 	Georgia	Cobb County, GA	Dekalb County, GA	Fulton County, GA	Gwinnett County, GA

Total Asian	320,905	31,164	37,095	52,213	86,957

Chinese (except Taiwanese)	44,604	4,961	5,767	10,025	10,624

Taiwanese	3,483	378	525	959	886


Disinfectant	Concentrations tested (contact time in minutes used)	Effective	Level of Evidence	Comments	Reference

Chlorhexidine gluconate	<0.02% (1440), 0.5% (0.5), 2% (2), 4% (3, 180, 1800)	Yes	Good	Most studied antiseptic. Limited clinical evaluation.	Schelenz et al., 2016; Abdolrasouli et al., 2017; Moore et al., 2017; Sherry et al., 2017

Chlorhexidine gluconate in isopropyl alcohol	2%/70% (2)	Yes	Low	In vitro testing only.	Moore et al., 2017

Povidone-iodine	10% (2, 3, 180, 1800)	Yes	Moderate	In vitro testing only.	Abdolrasouli et al., 2017; Moore et al., 2017;

Alcohol	70%	Yes	Low	Limited clinical evaluation.	Biswal et al., 2017


	Hyperkalaemia (≥6 mmol/L)*	Creatinine ≥220 μmol/L	≥30% increase in creatinine

Number with adverse biochemical values†	128/6373 (2.0%)	177/6520 (2.7%)	877/6520 (13.5%)

Number discontinuing AA‡	68/128 (53.1%)	76/177 (42.9%)	251/877 (28.6%)


Clean-up method	According to reference	Total solvent (mL)	Time (h)	Swelling (%)	Release of oligomers (%)

Soxhlet extraction ethylacetate	Smedes and Booij (2012)	400	100	92	2.5

Extraction ethylacetate	Shahpoury and Hageman (2013)	400	48	76	2.4

Extraction n-hexane/acetone (3:1)	Schäfer et al.(2010)	800	96	124	2.5

ASE n-hexane/acetone (1:1)	This study	169	1.2	42	2.2


	Recurrence	No recurrence	p value

n	9		187

Mean age (SD)	55.3	(13.9)	55.9	(12.1)	n.s.

Stagea

I	2		87

IIA or B	4		96		<0.01

IIIA or B	3		4

Histology

Ductal	7		161

Lobular	2		11		n.s.

Others	0		15

High nuclear grade	11%	(1/9)	4%	(7/181)	n.s.

High histological grade	22%	(2/9)	4%	(6/141)	n.s.

ERb	100%	(9/9)	100%	(187/187)	n.s.

PRb	67%	(6/9)	78%	(145/187)	n.s.

Mean Ki67 (%) (SD)	37.9	(21.7)	24.1	(18.5)	<0.05

(Neo-) adjuvant therapy

Endocrine + chemotherapy	9		52

Endocrine therapy only	0		127

Chemotherapy only	0		1

None	0		7


Category	Value

Total patients enrolled	80

Number of groups	15

Number of geographic areas with groups	9

Average number of patients per group	5.3

Female, number (%)	51 (63.8%)

Age at enrollment (years), median (IQR)	44 (36–51)

CD4 count at enrollment (cells/mL), median (IQR)	509 (382–670)

Months on ART prior to enrollment, median (IQR)	45.2 (22.4–65.6)


PhenX family history of MI?	PMRP family history of MI/Angina

Yes	No	Yes	No

N	%	N	%	N	%	N	%

1108	52.8	991	47.2	589	28.1	1510	71.9

Kappa=0.352 (95% CL=0.317, 0.386)


Combined category	Includes	Constructed for wave

Any mood disorder	MDD, Dysthymia	1 and 2

Any anxiety disorder W1	Panic disorder, Agoraphobia without a history of panic disorder, Specific phobias, Social phobia, GAD, OCD, PTSD.	1

Any Anxiety disorder W1–2	Panic disorder, Agoraphobia without a history of panic disorder, Specific phobias, Social phobia, GAD.	1 and 2

Any anxiety disorder W1–2 excluding specific phobias	Panic disorder, Agoraphobia without a history of panic disorder, Social phobia, GAD.	1 and 2

AUD	Alcohol abuse, Alcohol dependence.	1 and 2

Any mental disorder W1	Any mood disorder, Any anxiety disorder W1, AUD.	1

Any mental disorder W1–2	Any mood disorder, Any anxiety disorder W1–2, AUD.	1 and 2

Any mental disorder W1–2 excluding specific phobias	Any mood disorder, Any anxiety disorder W1–2 excluding specific phobias, AUD.	1 and 2

Categories only presented in Supplementary table

Drug use disorder	Drug abuse, drug dependence.	1

Any substance use disorder	Drug use disorder, AUD.	1

Any disorder W1- supplement	Any mood disorder, Any anxiety disorder W1, Any substance use disorder	1


Parameters	Value

Number of unigenes	68,961

Number of transcripts	134,793

Average unigene length (bp)	1322

Average transcript length (bp)	1600

Unigene N50 (bp)	1721

transcript N50 (bp)	2263

Minimum unigene length (bp)	201

Minimum transcript length (bp)	201

Maximum unigene length (bp)	15,890

Maximum transcript length (bp)	15,890


A	B	C	D	E	F	G	H	I	J	K

1	24	LD	Good	86	48 + 8	Screw track infection	12	90/85	Excellent	10–40

2	24	RS	Good	36	13 + 7	–	12	89/78	Excellent	15–50

3	24	Repair	Good	27	9 + 5	Superficial infection	6	91/80	Excellent	10–30

4	12	RS	Good	60	13 + 6	–	6	91/81	Good	5–20

5	24	RS	Good	97	8 + 7	–	9	89/80	Good	15–60

6	12	RS	Fair	62	44 + 5	Superficial infection	6	90/78	Good	5–30

7	24	Repair	Good	26	8 + 6	–	6	88/75	Excellent	15–50

8	24	RS	Good	28	10 + 9	–	6	87/77	Excellent	10–40

9	36	ALT	Good	83	36 + 7	–	12	94/77	Excellent	5–30

10	24	Repair	Good	32	22 + 8	–	6	90/80	Good	10–40

11	24	Repair	Good	27	21 + 8	Screw track infection	6	91/79	Good	20–50

12	12	Repair	Good	47	9 + 6	–	12	95/81	Good	10–30

13	12	Repair	Good	31	13 + 9	–	6	90/80	Good	10–40

14	24	LD	Good	54	26 + 7	–	6	93/80	Excellent	10–50

15	24	RS	Good	97	11 + 9	–	6	87/84	Good	10–40

16	12	Repair	Good	51	27 + 11	–	12	90/75	Good	10–20


Patient characteristics

Mean age	Years 40.3	SD 16.4	Min 27.0	Max 55.0

Median length of stay	Years 5.5	SD 6.8	Min 0.5 yrs	Max 33.5 yrs

Ward location

Low secure hostel	6 [12%]

Low secure rehabilitation ward	11 [20%]

Medium security rehabilitation	15 [29%]

Medium security sub-acute	14 [27%]

High secure [long stay]	6 [12%]

Community leave status

Community leave	36 [70%]

No community Leave	16 [30%]

Primary Diagnosis

Schizophrenia/ Schizoaffective disorder	52 [100%]


	5 Fr Catheters (n = 49)	7 Fr Catheters (n = 48)	P

Total discomfort#1	3.2 ± 0.2	3.9 ± 0.2	0.018

Difficulty with eating#1	2.2 ± 0.1	2.7 ± 0.2	0.079

Nasal hemorrhage#2	1 (2)	0 (0)	0.320

Sore throat#2	6 (12)	9 (18)	0.376

Nausea#2	0 (0)	1 (2)	0.310

Caught on a nearby object#2	1 (2)	1 (2)	0.988

Other adverse events#2	10 (20)	10 (20)	0.481


Error number:Check the appropriate boxes	Physician assessment number: 1 or 2

Potential severity according to the Medication Error Index (3)

No consequences for the patient

An error avoided that would not cause patient harm

An error avoided that would require monitoring to confirm that it did not result in patient harm

Temporary damage	Potential clinical consequences	Potential hospitalisation and treatment*

An error avoided that could have contributed to temporary harm to the patient, requiring intervention	Acute renal failure	Hospitalisation

	Cardiac toxicity	Prolongation of the initial hospitalisation

	Skin toxicity	New hospitalisation

An error avoided that could have contributed to temporary harm to the patient, requiring initial or prolonged hospitalisation	Neutropenia	Type of ward

	Thrombopenia	Standard hospitalisation unit

	Anemia	Day-care unit

	Febrile neutropenia	Intensive care unit

	Neurotoxicity	Number of additional days of hospitalisation

Permanent damage	Hepatic cytolysis	Treatments

An error avoided that could have contributed to permanent patient harm	Hepatic cholestasis	Platelet transfusions

Compromised vital prognosis	Diarrhea	Erythrocyte transfusions

An error avoided that could have required intervention necessary to sustain life	Vomiting	Granulocyte Colony Stimulating Factor

Patient death	Other:	Parenteral nutrition

		Other:

An error avoided that could have contributed to the patient's death


 	GG n = 146	GC/CC n = 64	p value

Infection type

Gram-negative	62%	81%	0.0062

Gram-positive	83%	83%	1.0000

Fungal	52%	58%	0.4565

Viral	18%	17%	1.0000

Parasitic	0%	0%

Other	1%	3%


Stem cell source	Benefits	Drawbacks

	Donor	Recipient	Donor	Recipient

BM		Lower risk of GvHD	More invasive HSC collection

PBSC	No general anesthesia for collection; less discomfort and pain	Faster hematopoietic engraftment and immune reconstitution; enhanced GvL effect		Higher risk of GvHD

CB	Non-invasive	Lower risks of GvHD and relapse; rapid availability; increased level of HLA-disparity tolerated		Lower number of HSCs; slower immune reconstitution


Characteristic	Unit	Recommended values (Santos and Borem, 2013)	CTC20	CTC175-A

Fiber	% sugarcane	10–13	10.72	10.41

Starch	mg/kg	<1,000	875	948

Brix	% juice	>14	21.02	20.84

Dextran	mg/kg	<10	<10	<10

RS	% juice	<0.8	0.47	0.47

TRS	% juice	>15	20.54	20

pH	–	4.8–5.8	5.4	5.3

Pol	% juice	>14	19.43	19.26

Purity	% juice	>85	92.44	92.42


CNE	Mt	Zt	Mg	Zg	Trans&Gene	NoTrans&Gene

Hs259	Limbs	+	-	+	-	Yes

Spinal cord	-	+	+	+

Hs327	Hindbrain	+	+	+	+

Forebrain	-	+	+	+

Spinal cord	+	+	+	-	 	Yes

Midbrain	-	+	+	+

Hs382	Forebrain	+	+	+	+

Somites	+	+	+	+

Spinal cord	+	-	+	+

DRG	+	-	+	-	Yes

Eye	-	+	+	+

Notochord	-	+	+	+

Hindbrain	+	-	+	+

Midbrain	+	-	+	+

Hs422	Forebrain	+	+	+	+

Spinal cord	-	+	-	-

Nose	+	-	+	-	Yes

Hindbrain	-	+	-	-

Hs595	Forebrain	+	+	+	+

Midbrain	+	-	+	+

Nose	+	-	+	-	Yes

Hs609	Forebrain	+	-	+	+

Limbs	+	-	+	-	Yes

Hs671	Forebrain	+	+	+	+

Eye	-	+	+	+

Hindbrain	-	+	+	+

DRG	-	+	+	-

Hs672	Forebrain	+	-	+	+

Midbrain	+	+	+	+

Spinal cord	+	-	+	-	Yes

Hs687	Forebrain	+	+	+	+

Spinal cord	+	-	+	-	Yes

Hs774	Hindbrain	+	+	+	+

Limbs	+	+	+	-	 	Yes

Forebrain	-	+	+	+

Eye	-	+	-	+	Yes

Hs1114	Midbrain	+	+	+	+

Hindbrain	+	+	-	+

Spinal cord	+	+	+	+


ISAV Sample(s)	Sequence direction	No. of trimmed reads	Percent of reads identical to Sanger sequence

SCN1a	HE gene forward	50552	82.4

	HE gene reverse	69684	91.4

	F gene forward	44498	91.9

	F gene reverse	49118	89.2

SCN pool 	HE gene forward	25695	78.3

(SCN2, SCN3, SCN4)	HE gene reverse	68481	92.2

	F gene forward	31230	92.1

	F gene reverse	35799	89.5

OBK1b	HE gene forward	52038	92.4

	HE gene reverse	88172	93.0

	F gene forward	31546	91.4

	F gene reverse	46835	89.7

OBK pool 	HE gene forward	40458	92.1

(OBK2, OBK3, OBK4)	HE gene reverse	51772	92.8

	F gene forward	45909	91.9

	F gene reverse	44498	91.9


Treatment	Total cells	Eosinophils	Monocytes	Lymphocytes	Neutrophils

PBS	240 ± 38§	3 ± 1§	201 ± 18	8 ± 5§	10 ± 7

Dpt+Vit A 50	612 ± 36	293 ± 28	198 ± 24	86 ± 15	34 ± 8

Dpt+Vit A 500	624 ± 59	312 ± 29	199 ± 22	82 ± 12	29 ± 7

Dpt+Vit A 2500	428 ± 46	46 ± 35*	284 ± 34	79 ± 11	19 ± 7


Reporting criteria	CDE Programme

Where was the intervention delivered and why?	Primary care settings (GP surgeries) and community settings with a single lay educator (or with the use of interpreters when necessary

What behavioural change theory has intervention been based on (if any)?	Social learning theory

What behaviour change techniques were used by people delivering the intervention (if any)*?	1, 2, 4, 6, 8, 10, 19, 22, 24

A description of the activities and material provided in each workshop and their intended outcomes?	Material: information on weight management, choosing healthier foods, meal planning, physical exercise, checking and improving metabolic control and preventing complications.

Activities: participants taking each other’s blood pressure, BMI calculations, understanding sugar and salt content in foods, Eat-well plate, food maps, guided imagery, ‘freethink’.

Intended outcomes: desirable body weight, learn to shop for food, increase physical activity, take medication properly and regularly, recognise early symptoms of condition, regularly attend clinics, improved symptom control, reduced BMI, improved quality of life and knowledge of condition, reduced level of prescribing, slower disease progression, management of condition, carry out normal roles and activities, and manage emotional impact of illness.

What support (if any) was provided to individuals outside of workshops?	No contact outside of workshops.

Was a manual or protocol used to deliver the intervention and are there details on how it can be accessed?	Manual is available to lay educators, however, not used during intervention. Can be accessed via permission from Health Exchange.

How were individuals referred to the programme?	Patients suffering from diabetes mellitus, coronary heart disease and/or chronic kidney disease were invited to attend the programme. Patients referred to the programme by general practitioners, practice nurses or practice staff. Practices citing a lack of time asked CDEs to contact patients on chronic disease registers directly by phone or postal mail.

Were any cultural or structural adaptations used?	Delivery in various languages, cultural adaptation of educational material, application of visual aids and demonstrations, understandable terminology, emotional well-being, culturally sensitive approach to delivery, recruitment of lay personnel, delivery in community locations, and religious/cultural acknowledgement.


	Low utilization	Intermediate utilization	High utilization

	Median	IQR	Median	IQR	Median	IQR

Volume measures (n)

 Annual PICU admissions	1582	(977, 2602)	2283	(1678, 2657)	1614	(1475, 2241)NS

 Annual cardiac surgical volume	184	(116, 340)	233	(145, 314)	224	(180, 249)NS

PICU severity of illness measures (%)

 Mechanical ventilation admits	36.8%	(26.9, 53.4)	43.9%	(37.5, 46.9)	36.9%	(31.3, 45.2)NS

 APR DRG SOI category 3	32.4%	(28.7, 34.3)	31.7%	(29.0, 33.7)	30.5%	(29.7, 34.0)NS

 APR DRG SOI category 4	20.3%	(15.2, 22.2)	24.2%	(17.4, 27.2)	20.7%	(19.1, 21.9)NS


Measured variables	Pretest(n = 17)	Posttest(n = 17)	Test power	Effect size

Mean ± SD	Mean ± SD

SMMI	8.97 ± 1.69	10.52 ± 2.35	0.95	0.7529

Physical fitness

 Standing on one foot (seconds)	3.30 ± 7.19	7.36 ± 12.32	0.95	0.4023

 Shoulder–arm flexibility (centimeters)	−37.50 ± 16.33	− 28.56 ± 13.94	0.95	0.5884

 8-ft up and go test (seconds)	36.2 ± 24.57	22.00 ± 17.25	0.95	−0.7091

 Grip strength (kilograms)	11.19 ± 7.36	14.45 ± 7.48	0.95	0.4399

 Five repeated sit-to-stand tests (seconds)	42.42 ± 22.98	30.58 ± 15.31	0.95	−0.6063


Scenario	Deaths per 1,000 live births in 2010 (95% CI)	Annualized rate of decline, 1990–2010 (95% CI)

Currently estimated values	111 (108, 115)	2.2% (2.0–2.4%)

Counterfactual at 2005 coverage levels	119 (114, 123)	1.9% (1.7–2.1%)

Counterfactual at 2000 coverage levels	124 (118, 129)	1.7% (1.5–1.9%)


GO-ID	Term	Categorya	FDRb	P-Value	#Test	#Ref	#notAnnot Test	#notAnnot Ref

GO:0005506	iron ion binding	F	3.99E-07	9.40E-11	17	153	115	9554

GO:0055114	oxidation-reduction process	P	1.09E-06	6.16E-10	31	636	101	9071

GO:0016491	oxidoreductase activity	F	1.09E-06	7.68E-10	31	642	101	9065

GO:0004497	monooxygenase activity	F	6.16E-06	5.87E-09	13	106	119	9601

GO:0020037	heme binding	F	6.16E-06	8.61E-09	15	157	117	9550

GO:0046906	tetrapyrrole binding	F	6.16E-06	9.33E-09	15	158	117	9549

GO:0044710	single-organism metabolic process	P	6.16E-06	1.02E-08	52	1747	80	7960

GO:0016705	oxidoreductase activity, acting on paired donors, with incorporation	F					117	9534

	or reduction of molecular oxygen		1.53E-05	2.88E-08	15	173

GO:0003824	catalytic activity	F	5.33E-03	1.13E-05	75	3644	57	6063


Gingival index	Number of patients

0	23

1	55

2	16

3	14

Total	108


Peptide	Sequence	Portal vein (nM/h)	Jugular vein (nM/h)	CL Rat (mL/min/Kg)	Liver first pass effect (%)

(4)	[Abu-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro]	1839	1656	41	11

(5)	[Ala-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro]	449	104	70	77


Postal	Electronic

Monetary or non-monetary incentives	Non-monetary incentives

Teaser on the envelope	Personalised questionnaires

Pre-notification	Include pictures

Follow-up with another copy included	Not including ‘survey’ in subject line

Handwritten addresses	Male signature

University sponsorship	White background

Use recorded delivery	Short questionnaire

Include return envelope	Offer of results

Avoid sensitive questions	Statement that others have responded


	Control	iStroke	P

Time, minutes, mean ± SD	14.6 ± 7.4	7.3 ± 5.2	0.010

Total missed contraindication counts, n (%a)	23 (42.6)	7 (13.0)	0.001

Missed contraindication counts per physician

 Mean ± SD	1.9 ± 0.7	0.6 ± 1.0	0.001

 Median	2.0	0	0.002

Missed contraindication counts per item

 Mean ± SD	3.8 ± 2.5	1.2 ± 1.5	0.047

 Median	3.5	1.0	0.027


Mutation	Score	Confidence	Domain	Prediction

R61W	0.773	Sensitivity: 0.76	EGF-like 1	Possibly damaging

Especificity: 0.86

R75P	0.884	Sensitivity: 0.71	EGF-like 1	Possibly damaging

Especificity: 0.89

D80G	0.694	Sensitivity: 0.78	EGF-like 2	Possibly damaging

Especificity: 0.85

R213K	0.171	Sensitivity: 0.89	EGF-like 5	Benign

Especificity: 0.72


Source	Df	F

Species	8	24.6***

Water Level	1	13.3***

Species* Water	8	1.2


Bacterial strains/Plasmids	Characteristic	Source/Reference

Brucella ovis

PA	virulent strain, natural NalR	CITA collection

BoΔwadA	PA in frame deletion mutant in wadA Δ58-679	This work

BoΔwadB	PA in frame deletion mutant in wadB Δ49-195	This work

BoΔwadC	PA in frame deletion mutant in wadC Δ17-306	This work

BoPA-Gm	challenge strain, PA GmR	UN collection

Brucella melitensis

Rev 1	reference vaccine	CITA collection

E. coli

S17-1 λpir	mating strain with plasmid RP4 inserted into the chromosome	Simon et al. [[19]]

TOP10 F’	F−lacIq Tn 10 (TetR) mcrA Δ(mrr-hsdRMS-mcrBC) 80lacZ ΔM15 ΔlacX74 recA1alaD139 endA1 nupG	Invitrogen

Plasmids

pCR2.1	cloning vector	Invitrogen

pJQK	derivated of pJQ200KS+; KmR, GmS	Scupham and Triplett [[20]]

pYRI-12	913-bp of B. abortus parental chromosomal DNA containing the wadA deletion allele, generated by PCR and cloned into pCR2.1	This work

pYRI-13	BamHI-XbaI fragment from pYRI-12 cloned into the corresponding sites of pJQK	This work

pYRI-1	570-bp of B. abortus parental chromosomal DNA containing the wadB deletion allele, generated by PCR and cloned into pCR2.1	Gil-Ramírez et al. [[7]]

pYRI-2	BamHI-XbaI fragment from pYRI-1 cloned into the corresponding sites of pJQK	Gil-Ramírez et al. [[7]]

pYRI-14	934-bp of B. ovis parental chromosomal DNA containing the wadC deletion allele, generated by PCR and cloned into pCR2.1	This work

pYRI-15	BamHI-XbaI fragment from pYRI-14 cloned into the corresponding sites of pJQK	This work


Age	P0–P1a	P10	P21

Dnaaf1m4Bei	Observedb	Expected	Observedc	Expected	Observedd	Expected

 Wild-type	29	20.5	21	17.5	12	8.25

 Heterozygote	39	41	43	35	21	16.5

 Homozygote	14	20.5	6	17.5	0	8.25

Laterality defect	8 (57.1%)		2 (33.3%)		N/Ae

 Situs inversus	3		0

 Heterotaxy	5		2

Lrrc48m6Bei	Observed	Expected	Observed	Expected	Observed	Expected

 Wild-type	21	18	24	19.75	22	17.75

 Heterozygote	33	36	36	39.5	31	35.5

 Homozygote	18	18	19	19.75	18	17.75

Laterality defect	2 (11.1%)		1 (5.3%)		N/Ae

 Situs inversus	2		0

 Heterotaxy	0		1


Cell type	Stimulation	Type of HA binding	HA receptor	Reference

Monocyte (human)	TNFα, LPS, IL-1, IFN-γ	Inducible	CD44	(59–61)

Alveolar macrophages (human, rodents)	None	Constitutive	CD44	(17, 46 –48, 50)

Peritoneal macrophage (mouse)	LPS with IFNγ, or IL-4	Inducible	CD44	(62)

Bone marrow-derived macrophages (mouse)	LPS with IFNγ, TNFα, or IL-4	Inducible	CD44	(62)

Monocyte-derived DC (human)	CD40L expressing fibroblasts	Inducible	CD44	(63)

B cells (human, mouse)	PMA, IL-5, LPS	Inducible, a subset binds	CD44	(64 –67)

T cells (mouse)	PMA/ionomycin, CD3 antibodies, specific antigen, or superantigen	Inducible, often a subset binds	CD44	(54, 55, 68)

CD4+ CD25+ T regulatory cells (human and mouse)	CD3 +/− CD28 activation	Inducible, a subset binds	CD44	(69, 70)

Neutrophil (mouse)	LPS induced liver inflammation in vivo	Binding to SHAP modified HA	CD44, not RHAMM	(71)

NK cells (mouse)	IL-2, IL-15	Inducible, a subset binds	CD44	(72)

Platelets (mouse)	None	Constitutive	CD44	(73)


Compound	Elution time (min)	Fraction theoretically contained in

Phenylalanine	5.964 ± 0.003	B

Caffeic acid	13.471 ± 0.170	C

Coumaric acid	15.941 ± 0.208	D

Vanillin	16.187 ± 0.065	D

Cinnamic acid	23.595 ± 0.155	E

Capsaicin	32.801 ± 0.053	G


Group Variables 	With iron deficiency	Without iron deficiency	P-value

Type of febrile seizure 	Simple	12(37.5%)	20(62.5%)	0.04

Complex 	12(66.7%)	6(33.3%)


Strain	Gene name	Protein name	Metabolic function	Fold change

P5	TPI1	Triosephosphateisomerase	Glycolisis	27.28

AHP1	Peroxiredoxin type-2	Oxidative stress	20.07

PDC1	Pyruvate DeCarboxylase	Glycolisis, Glucose fermentation	13.95

TSA1	Thioredoxin peroxidase	Oxidative stress	5.28

CDC19	Pyruvatekinase	Glycolisis, Glucose fermentation	5.16

ENO2	Enolase II, phosphopyruvatehydratase	Glycolisis	3.28

FBA1	Fructose 1,6-bisphosphate aldolase	Glycolisis	2.15

P24	RPL31A	Ribosomal Protein of the Large subunit	Structural constituent of ribosome	17.65

TDH1	Glyceraldehyde-3-phosphate dehydrogenase	Glycolisis	7.11

TEF1	Translational elongation factor EF-1 alpha	Translation	5.12

TDH3	Glyceraldehyde-3-phosphate dehydrogenase	Glycolisis	4.76

GPM1	Glycerate phosphomutase	Glycolisis	3.53

ENO2	Enolase II, phosphopyruvatehydratase	Glycolisis	-4.09


Protein	Species	Mitochondrial function	Stimulus driving mitochondrial localization	Reference

NF-κB	Rat, mouse	Suppression of mitochondrial genes	Steady-state conditions	Johnson et al., 2011; Johnson and Perkins, 2012

CREB	Rat, mouse	Activation of mitochondrial genes	Steady-state conditions	Lee et al., 2005; Ryu et al., 2005

MEF-2D	Mouse	Transcriptional Activation of ND6	Steady-state conditions	She et al., 2011

TERT	Human, mouse, Rat	Reverse Transcription of mitochondrial tRNAs,Protection from mtDNA damage	Oxidative stress, steady state conditions	Haendeler et al., 2009; Sharma et al., 2012; Saretzki, 2014

RECQL4	Human, mouse	Restores mtDNA replication, Ensures mtDNA integrity	Steady-state conditions	De et al., 2012; Gupta et al., 2014; Wang et al., 2014; Lu et al., 2016

STAT3	Mouse, human	Modulation ETC through direct binding to respiratory complexes	Steady-state conditionsActivated Ras	Gough et al., 2009; Wegrzyn et al., 2009

P53	Rat, mouse, human	Modulation of mitochondrial permeability, apoptosis and necrosis,Promotion of mtDNA accuracy and stability.	Pro-apoptotic signals, oxidative stress, hypoxia, ultraviolet irradiation	Jiang et al., 2006; Marchenko et al., 2007; Bakhanashvili et al., 2008; Vaseva et al., 2012

IRF3	Human	Apoptosis induction by mitochondrial recruitment of BAX	RNA virus infection	Chattopadhyay et al., 2010

STAT1	Mouse, Rat	ND	Steady-state conditions	Boengler et al., 2010

HIF-1α	Human	ND	Hypoxia	Briston et al., 2011


Growth and nutritional status of rats

	Body weight gain (g)	Liver weight (g)	Food intake (g/day)	Water intake (ml/day)	Feed efficiency (B.W gain/food intake)

C	16.4 ± 6.67a	6.92 ± 1.42 a	16.03 ± 2.47a	9.33 ± 1.91 ab	1.02

FSO	24.55 ± 9.7 a	8.15 ± 0.83 b	14.94 ± 1.82 ab	10.04 ± 1.53 a	1.64

OSO	20.33 ± 7.81 a	7.54 ± 0.64 ab	13.74 ± 2.41c	9.82 ± 1.5 ab	1.47

MG	25.83 ± 6.64 a	7.27 ± 0.7 a	14.24 ± 2.17 bc	9.07 ± 1.22 b	1.81


Size	5 μm	10 μm	15 μm	20 μm

Breakdown voltage	21.25 V	12 V	11.8 V	11.7 V

Dark current	200 pA	60 pA	85 pA	106 pA


Point	Details

1	Five sites per organ

2	Avoidance of pressure artefacts

3	Elimination of secretions

4	Adequate focus and contrast adjustment

5	High quality recording


			Unstandardized estimates	S.E.	C.R.	P	Standardized estimates

PRIVATE HEALTH INSURANCE COVERAGE	<---	PERCEIVED HEALTH	-.038	.014	2.825	.005	-.010

PRIVATE HEALTH INSURANCE COVERAGE	<---	PERCEIVED NEED	-.041	.029	-1.403	.161	-.08

PRIVATE HEALTH INSURANCE COVERAGE	<---	PERCEIVED VALUE	-.041	.014	-2.875	.004	-.07

PRIVATE HEALTH INSURANCE COVERAGE	<---	SES	.071	.014	5.230	***	.24

PRIVATE HEALTH INSURANCE COVERAGE	<---	GENDER	.006	.027	.225	.822	-.06

PRIVATE HEALTH INSURANCE COVERAGE	<---	AFRICAN AMERICAN	-.175	.037	-4.742	***	-.226

PRIVATE HEALTH INSURANCE COVERAGE	<---	HISPANIC	-.252	.034	-7.332	***	-.18


Inclusion criteria	Exclusion criteria

1. Study design: interventional or observational	1. Studies of exclusively pediatric population (age <18 years)

2. Included population: hospitalized aSAH patients	2. Non-human studies

3. Included intervention: RBC transfusion	3. Duplicates or ‘sub-cohorts’ of previously published cohorts

4. Comparator: a different transfusion threshold or no transfusion

5. Study outcome: any


MIxS-BE term

Carbon dioxidea

Ventilation typea

Organism counta

BE core

 Surface material

 Surface-air contaminant

 Relative air humidity

 Absolute air humidity

 Surface humidity

 Air temperature

 Surface temperature

 Surface moisture pH

 Surface moisture

 Dew point

 Building occupancy type

BE Building properties

 Indoor space (room type)

 Indoor surface

 Filter type

 Heating and cooling system type

 Substructure type

 Building setting

 Light type

BE Sample properties

 Sample size sorting method

 Space typical state

 Typical occupant density

 Occupancy at sampling

 Occupant density at sampling


Dose studied	100 μg	200 μg	400 μg	600 μg	800 μg

1	√		√

2	√			√

3		√			√

4		√	√


Treatments	Species	Duration	Metabolic disorders	Potential mechanism	Reference

0–250 μmol/l capsaicin	3T3-L1 preadipocytes and adipocytes	24–72 h	Decreased the amount of intracellular triglycerides, GPDH activity	Inhibited the expression of PPARγ, C/EBP-α, and leptin	Hsu et al. [52]

			Induced apoptosis	Induced up-regulation of adiponectin at the protein level

			Inhibited adipogenesis

1 μmol/l capsaicin	3T3-L1 preadipocytes	3–8 days	Prevented the adipogenesis	Increased intracellular calcium	Zhang et al. [53]

0.015% capsaicin	Male C57BL/6 mice	10 weeks	Decreased triglyceride levels	Decreased TRPV-1 expression in adipose tissue	Kang et al. [54]

			Lowered fasting glucose, insulin, and leptin levels	Increased mRNA/protein of adiponectin in the adipose tissue

				Increased PPARα/PGC-1α mRNA in the liver

10 mg/kg body weight capsaicin	Std ddY mice	2 weeks	Lower body weight	Increased oxygen consumption	Ohnuki et al. [55]

			Markedly suppressed body fat accumulation	Stimulated the secretion of adrenalin

			Decreased triglyceride levels

0.3% capsinoids	C57BL/6J mice	8 weeks	Suppressed body weight gain under the HFD	Increased energy expenditure	Saito et al. [57], Ohyama et al. [58]

			Decreased plasma cholesterol level	Activation of fat oxidation in skeletal muscle

			Prevented diet-induced liver steatosis	Activation lipolysis in BAT

				Increased cAMP levels and PKA activity in BAT

0.003%, 0.01%, and 0.03% capsaicin	wild-type and TRPV1−/− mice	16 weeks	Promoted weight loss	Increased the expression of UCP-1, BMP8b, SIRT-1, PGC-1α, and PRDM-16 in BAT	Baskaran et al. [59]

			Enhanced the respiratory exchange ratio	Increased the phosphorylation of SIRT-1

			Countered hypercholesterolemia

0.01% capsaicin	wild-type and TRPV1−/− mice	26 weeks	Countered obesity	Promoted SIRT-1 expression	Baskaran et al. [60]

			Browning of WAT	Increased the expression of PGC-1α

				Facilitated PPARγ–PRDM-16 interaction

0.01% capsaicin	wild-type and TRPV1−/− mice	24 weeks	Ameliorated abnormal glucose homeostasis	Activation of TRPV1-mediated GLP-1 secretion in the intestinal cells	Wang et al. [49]

			Increased GLP-1 levels in the plasma and ileum

640 μmol/L, 2 ml/kg capsaicin	Sprague-Dawley rats	15 min	Increased superior mesenteric artery blood flow	Induced a dichotomous pattern of blood flow changes	Leung et al. [68]

			Reduction in hydrogen gas clearance

0.01% capsaicin	C57BL/6J male mice	9 weeks	Reduced weight gain	Modest modulation of the gut microbiota	Shen et al. [69]

			Improved glucose tolerance	Up-regulated the expression of Muc2 and antimicrobial protein gene Reg3g in the intestine


Themes	Subtheme	Item

LEADERSHIP/Governance	Systematic Approach	Giving no priority to the discharge planning in heath systemLack of comprehensive plan to develop discharge planning in the ministry of healthLack of patient-centered approach in the health systemLack of systematic and comprehensive approach to the planDisregarding the holistic care in training curriculum

Structure	Lack of referral system and rationing of health services systemLack of structured, systematic and coordinated systemLack of comprehensive benefit packageLack of specific standards, rules, regulations on discharge planning

Management	Low willpower of senior managersPoor monitoring and evaluation systemPoor and inefficient management in heath systemManagers and policy makers’ inaccurate comprehension of discharge planning

Communication	Poor inter and intra sectional contributionLack of defined interaction and communication among medical personnel to provide careWeakness in written supportive policies on discharge planning

Advocacy	Lack of home care system in health systemLack of powerful supportive centers (such as community-based organizations)


	Treatment	DF	F-value	P-value	R-square

Emergence Holes	Depth (D)	4	19.90	<0.001	68.53

Volume (V)	2	83.25	<0.001

Error	113

Air holes	Depth (D)	4	22.51	<0.001	71.60

Volume (V)	2	97.46	<0.001

Error	113

Seed Weight	Depth (D)	4	19.00	<0.001	56.84

Volume (V)	2	36.41	<0.001

Error	113


		Mcm2 immunoreactivity

Variable	Categorisation	n analysable	negative (<40%)	positive (≥40%)	pa

Clinico-pathologic data:

Age at diagnosis

	<65 years	47	27	20	1.000

	≥65 years	63	37	26

Gender

	male	72	39	33	0.593

	female	57	34	23

Ann Arbor Stage

	1	15	10	5	0.342

	2	34	15	19

	3	23	14	9

	4	35	22	13

International prognostic index

	0	2	2	0	0.122

	1	48	27	21

	2	21	14	7

	3	20	13	7

	4	14	4	10

Bone marrow involvement

	no	72	39	33	0.414

	yes	35	22	13

Extranodal involvement

	no	40	27	13	0.103

	yes	62	31	31

Bulky disease

	no	62	44	20	0.003

	yes	35	13	22

Serum levels of LDH at diagnosis

	<300 U/l	42	23	19	0.505

	≥300 U/l	41	26	15


Fibroblast	PD+/− rotenone (R)	Number of DEGs

MRC-5	PD38 − R to PD38 + R	1

PD42 − R to PD42 + R	2086

PD48 − R to PD48 + R	3527

PD52 − R to PD52 + R	319

HFF	PD22 − R to PD22 + R	1

PD26 − R to PD26 + R	4873

PD30 − R to PD30 + R	8151

PD34 − R to PD34 + R	6424

PD58 − R to PD58 + R	5726

PD74 − R to PD74 + R	60


Common name	Species	LTA	LTB

Deer mouse	Peromyscus maniculatus	AY251294	AY282503

House mouse	Mus musculus	NM_010735	MMU16984

Rat	Rattus norvegicus	NM_080769	BX883046

Woodchuck	Marmota monax	AF095586	AF095587

Human	Homo sapiens	AY216498	AY216497


miRNA	Regulation [17]	Potential regulation mechanism [17, 18]	Class [17]

miR-9-5p	Up	Chromosomal gain (1q)	Late

miR-15b-5p	Up	Chromosomal gain (3q)	Late

miR-28-5p	Up	Chromosomal gain (3q)	Early continuous

miR-100-5p	Down	Chromosomal loss (11q)	Late

miR-125b-5p	Down	Chromosomal loss (11q)	Late

miR-149-5p	Down	DNA methylation	Early continuous

miR-203a-3p	Down	DNA methylation	Early continuous

miR-375	Down	DNA methylation	Late


Animal	Skin non-midge fed**	Skin midge fed***	Tonsil	Lips	Lung

Sheep VH56/ 3 dpi	Minor engorgement, with indistinct vacuolation of epidermal cells.	Mildly oedematous/focal epidermal crusts/mild dermal inflammation *(lymphocytes, plasma cells and eosinophils).	Epithelial cells markedly vacuolated. Low numbers of eosinophils in tonsil itself.	Oedematous (especially around capillaries) and inflamed* (lymphocytes, plasma cells and eosinophils). Indistinct vacuolation of lip epidermal cells.	Peribronchial connective tissue is markedly oedematous and moderately inflamed*(lymphocytes, plasma cells and eosinophils).

Sheep VH67/ 4 dpi	Moderate oedema around capillaries and mild engorgement, mild aggregation of plasma cells around capillaries.	Moderately oedematous, especially around capillaries, with mild engorgement. Mild aggregation of plasma cells around capillaries, low numbers of neutrophils and eosinophils. Focal collagen necrosis.Note: C. sonorensis were last fed on this sheep 48 h prior to collection of skin samples.	Epithelial cells markedly vacuolated. Moderate numbers of eosinophils in connective tissue just below epithelium.	Focally dense aggregates of lymphocytes and plasma cells especially around capillaries and adnexae in mid dermis, lighter inflammation in superficial dermis.	Moderate inflammation *(lymphocytes, plasma cells) of peribronchial connective tissue.

Sheep VH58/ 6 dpi	Mild oedema and moderate engorgement, sparse dermal inflammation *(neutrophils, lymphocytes, plasma cells)	Moderately oedematous and engorged, with focal degeneration of epidermis. Moderate to marked diffuse dermal inflammation (Figure 2a) *(lymphocytes, plasma cells, eosinophils), with scattered foci of, predominantly, eosinophils associated with collagen necrosis.	Epithelial cells vacuolated. Glassy appearance to nuclei of macrophages, lymphocytes, plasma cells in lymphoid parenchyma.	Oedematous (especially around capillaries) and inflamed *(lymphocytes, plasma cells, eosinophils) – focally markedly so. Indistinct vacuolation of epidermal cells, but also apoptosis, epidermal oedema and erosion.	Peribronchial connective tissue is moderately oedematous and moderately inflamed *(plasma cells, lymphocytes).

Sheep VH57/ 8 dpi	Moderate oedema with mild perivascular inflammation *(lymphocytes and plasma cells).	Markedly oedematous (dermis and epidermis). Moderate to marked diffuse dermal inflammation around capillaries *(plasma cells, lymphocytes, eosinophils, neutrophils). Some crusts of surface and dermal foci of macrophages, plasma cells, lymphocytes and eosinophils, including granulomas in superficial dermis (neutrophils and eosinophils centrally with encircling epithelioid macrophages (Figure 2b).	Epithelial cells moderately to markedly vacuolated, numerous lymphocytes and plasma cells in epidermis. Glassy appearance to nuclei of macrophages, lymphocytes and plasma cells in lymphoid parenchyma.	Moderately oedematous (especially around capillaries) and moderately inflamed *(plasma cells, lymphocytes, rarely eosinophils).	Peribronchial connective tissue moderately oedematous and moderately inflamed *(plasma cells, lymphocytes). Diffuse engorgement and congestion.

Sheep VH66/ 9 dpi	Minor vacuolation of deep sweat gland cells as well as mild oedema with mild perivascular inflammation *(lymphocytes and plasma cells).	Moderate perivascular oedema and engorgement with patchy haemorrhage. One capillary contained a fibrin thrombus. Moderate to marked inflammation (plasma cells, lymphocytes, eosinophils, and neutrophils).	Areas of markedly vacuolated epithelial cells. There are also areas containing large numbers of lymphocytes and plasma cells in the tonsillar epithelium.	Engorged, haemorrhagic and oedematous (especially around capillaries) with mild inflammation *(plasma cells, lymphocytes, eosinophils and macrophages). Endothelial cells in the walls of some capillaries are degenerate.	Modest peribronchial inflammation *(plasma cells lymphocytes). Mild oedema, moderate engorgement, small numbers of vessels contain fibrin thrombi.


Attribute	Number (%)

Age

Mean Age	40.6 years

Standard deviation	9.1 years

Marital status (N = 220)

Married	229 (71.5)

Single	45 (14.1)

Widowed	49 (14.4)

Religion (N = 316)

Islam	182 (57.6)

Christian	134 (42.4)

Education (N = 300)

None	8 (2.7)

Primary	109 (36.3)

Secondary	155 (51.7)

Post-secondary	28 (9.3)

Ethnicity

Yoruba	284 (89.3)

Igbo	26 (8.2)

Hausa	8 (2.5)


gene	forward primer	reverse primer	probe

HPRT	5′-tgaacgtcttgctcgagatgtg-3′	5′-ccagcaggtcagcaaagaattt-3′	5′-tgggaggccatcacattgtagcc-3′

SNCA	5′-ccaaagagcaagtgacaaatgttg-3′	5′-agccagtggctgctgcaat-3′	5′-tgacgggtgtgacagcagtagccca-3′

5HT3AR	5-ggctggtgcacaagcaagac-3′	5-ggctggtgcacaagcaagac-3′	5-ctgcttggctgcgtcacctggttct-3′

5HT4R	5′-attccgggttgaacccttttc-3′	5′-aggtcttcggtagcgctcatc-3′	5′-acgtgccttcctcatcatcctct-3′

M3R	5′-cagctgcatacccaaaaccttt-3′	5′-tgaatgttttgttgcacagagcata-3′	5′-caacagcaccgtgaaccccgtgtg-3′

VIP	5′-aataaggcccagctccttgtg-3′	5′-cccaacctgagagcagaaggt-3′	5′-cttctcacagacttcggcatggc-3′


Property	Water	Blood	Units

Density ρ	1000	1050 [25]	kg/m3

Specific heat c	4190 [26]	3850 [25]	J/(kg · K)

Thermal conductivity k	0.61 [27]	0.53 [28]	W/(m · K)

Thermal diffusivity α = k/ρc	1.4 × 10-7	1.3 × 10-7	m2/s

Absolute viscosity μ	7 × 10-4 [26]	3.5 × 10-3 [29]	Pa · s

Kinematic viscosity ν = μ/ρ	7 × 10-7	3.3 × 10-6	m2/s

Coefficient of thermal expansion β	2.1 × 10-4 [26]	4.0 × 10-4 [30]	K-1


Rank	Feature description

1	Cumulative number of 30-day readmissions

2	Presence of acute respiratory failure ICD-9 code

3	Number of abnormal sodium level laboratory tests

4	Presence of pneumonia (organism unspecified) ICD-9 code

5	Number of abnormal chloride level laboratory tests

6	Presence of acute kidney failure (unspecified) ICD-9 code

7	Presence of diabetes (with other specified manifestations) ICD-9 code

8	Presence of acute kidney failure (any) ICD-9 code

9	Presence of respiratory failure, WKF

10	Presence of disorders of fluid electrolyte and acid-base balance (any) ICD-9 code

11	Presence of disorders of fluid/electrolyte/acid-base, WKF

12	Number of abnormal albumin level laboratory tests

13	Presence of asphyxia and hypoxemia ICD-9 code

14	Presence of anemia of chronic illness ICD-9 code

15	Presence of hypokalemia ICD-9 code


Location	Number

Spleen	14

Liver	13

Kidney	2

Diaphragm	2

Pancreas	2


Tap	Channel A	Channel B	Doppler

Relative Delay (ns)	Average Power (dB)	Relative Delay (ns)	Average Power (dB)	Spectrum

1	0	0.0	0	–2.5	Classic

2	310	–1.0	300	0	Classic

3	710	–9.0	8900	–12.8	Classic

4	1090	–10.0	12,900	–10.0	Classic

5	1730	–15.0	17,100	–25.2	Classic

6	2510	–20.0	20,000	–16.0	Classic


 	Invasive fungal rhinosinusitis with orbital complications (n = 35)	Bacterial rhinosinusitis with orbital complications (n = 65)	Adjusted odds ratio (95% CI)	P value

Nasal crust	14	1	77.78 (1.95–3095.00)	<0.001

Oculomotor nerve involvement	34	45	15.11 (2.16–644.26)	0.001

Trochlear nerve involvement	33	43	5.70 (0.52–62.57)	0.10

Optic nerve involvement	22	17	3.77 (1.50–9.50)	0.002

Abducens nerve involvement	33	45	3.70 (0.40–34.57)	0.22

Facial swelling	10	8	2.37 (0.82–6.80)	0.10

Trigeminal nerve involvement	16	13	1.62 (0.77–3.42)	0.20

Pus in middle meatus	16	27	1.36 (0.57–3.25)	0.49

Swelling of middle meatus	28	31	1.29 (0.55–3.04)	0.56

Secretion in nasopharynx	4	10	0.56 (0.18–1.73)	0.31

Proptosis	27	45	0.53 (0.16–1.79)	0.30

Periorbital swelling	20	58	0.32 (0.12–0.83)	0.01

Chemosis	27	53	0.26 (0.06–1.18)	0.06


Group	(1a) Ultramutated POLE mutant	(1b) Hypermutated dMMR/MSI	(2) CIN/SCNA-high, MSS

Mutation rate	++++	+++	+

Somatic copy number alterations	+/−	+	+++

Key molecular/genetic abnormality	POLE EDM proofreading mutation	Defective MMR/MLH1 promoter hypermethylation	Variety of mutated cancer genes; WNT pathway activation (mostly by APC mutation/inactivation)

Predominant histological type	Moderately differentiated adenocarcinoma	Mucinous, or signet ring, or poorly differentiated adenocarcinoma	Moderately differentiated adenocarcinoma

Proportion of all colorectal carcinomas	∼3 %	∼13 %	∼84 %

Prognosis	Good (more data required)	Good/poor after relapse	Good-poor (depending on other characteristics)


	N0S0	N0Sπ

	HH	LL	LH	HL	HH	LL	LH	HL

Obs. 1	Limited**				Limited**	Super*	Super

Obs. 2	Limited**	Limited**		Super	Limited**	Super		Limited**

Obs. 3	Limited**	Limited**	Limited**	Limited*		Super**	Super

Obs. 4	Limited**		Limited**	Limited**	Limited**	Super